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Preface 
 
Introduction 
Chronic kidney disease (CKD) is a progressive loss of kidney function.  The symptoms 
might include feeling generally unwell and experiencing a reduced appetite.  This disease is 
often diagnosed through the screening of people who are at high risk of getting kidney 
problems such as those with diabetes or high blood pressure.  Chronic kidney disease may 
also be identified when it leads to one of its recognized complications, such as 
cardiovascular disease, anemia or pericarditis [National Kidney Foundation, 2002].   
 
Chronic Kidney disease is identified by a blood test for creatinine.  A high level of 
creatinine in the blood indicates a low glomerular filtration rate (GFR) (the rate at which 
the kidney filters blood of all its impurities) and thus a low capacity of the kidney to excrete 
waste products.  Creatinine levels may be normal in the early stages of CKD and the 
condition is discovered if urinalysis (the testing of a urine sample) shows that the kidney is 
allowing the loss of protein or red blood cells into the urine.  To fully investigate the 
underlying cause of kidney damage, various forms of medical imaging, blood tests and 
often renal biopsy are employed to find out if there is a reversible cause for the kidney 
malfunction [National Kidney Foundation, 2002].   
 
Recent professional guidelines classify the severity of chronic kidney disease into five 
stages, with Stage 1 being the mildest and usually causing few symptoms and Stage 5 being 
a severe illness with poor life expectancy if untreated [National Kidney Foundation, 2002].  
End-stage kidney disease (ESKD), synonymous with Stage 5 CKD, is when kidney 
function has deteriorated to the point that life can no longer be sustained.  All individuals 
with a GFR < 60 mL/min/1.73 m2 for three months are classified as having CKD, 
irrespective of the presence or absence of kidney damage.  The rationale for including these 
individuals is that reduction in kidney function to this level or lower represents loss of half 
or more of the adult level of normal kidney function, which may be associated with a 
number of complications [National Kidney Foundation, 2002].  All individuals with kidney 
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damage are classified as having CKD, irrespective of the level of GFR; the rationale for this 
is that GFR may be sustained at normal or increased levels despite substantial kidney 
damage [National Kidney Foundation, 2002].  The loss of protein in the urine is regarded as 
an independent marker for worsening of kidney function and cardiovascular disease.  
Hence, the British guidelines append the letter “P” to the stage of chronic kidney disease if 
there is significant protein loss [National Institute for Health and Clinical Excellence, 
2008].   
 
A person with ESKD will require permanent renal replacement therapy for life.  Renal 
replacement therapy may be by dialysis or by kidney transplantation, with the latter being 
the best treatment for most people in terms of better quality of life and longer survival.  
Persons on renal replacement therapy have a higher risk for cancer than the general 
population, with persons with a transplant more at risk for cancer than persons on dialysis.   
 
Analysis of cancer risk in people with ESKD has tended to concentrate on risk either during 
dialysis or after transplantation.   However, since a graft has a finite life, persons switch to 
dialysis while waiting for a transplant.  Thus there could possibly be several switches back 
and forth between treatments over the life-course of an ESKD patient.  The first project 
examined cancer as a risk factor during a young (under 20 years at onset of ESKD) 
person’s entire life-course with ESKD and determined what effect it has on a person’s 
survival and the survival of a kidney graft.  It also described the cancers that person’s with 
ESKD had and determined if there was an association between the type of renal 
replacement therapy (dialysis or transplant) and getting a new cancer.  Using the data from 
the Australia and New Zealand Dialysis and Transplant Registry which collects data on all 
persons in whom renal-replacement therapy was started in Australia and New Zealand from 
1963, and restricting it to data for persons who were under the age of 20 years at the onset 
of ESKD, we examined cancer as a risk factor for a transplant failure and survival.   
Past research has shown that among all patients with ESKD, the survival rate is lower than 
the survival rate of the general population; this lower survival rate was also seen for a 
subgroup of patients who were children (under 20 years) when their ESKD began 
(McDonald and Craig, 2004).  However to the best of our knowledge no study has 
examined what additional effect, if any, cancer has on survival for these patients who were 
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children when their ESKD began.   Also to the best of our knowledge no research work has 
provided the cause-specific incidence proportion of deaths or the cause-specific survival 
among patients who were children when their ESKD began.  Research has also shown that 
patients with ESKD have a higher risk of acquiring cancer than the general population and 
have specified what cancers are most common among ESKD patients (Maisonneuve et al, 
1999).  However, to the best of our knowledge, no research work/s examines these findings 
for the subgroup of patients who were children when they acquired ESKD.   
The two related projects that form this portfolio were undertaken between August 2008 and 
June 2009.  Both projects involved analyzing data on all persons in the Australia and New 
Zealand Dialysis and Transplant Registry who were under 20 years of age when they 
started renal-replacement therapy (RRT).   
Student’s Role 
 
My role in each project was to prepare the data for analysis, provide suggestions on how 
the data could be analyzed, implement the agreed analysis plan, provide interpretation of 
the final results and write the report.   
 
Dr. Angela Webster provided invaluable support and advice on what type of analysis was 
appropriate for this study while Dr. Patrick Kelly provided invaluable support and advice 
on some of the technical aspects of the statistical analysis involved in the project.   
 
Reflections on learning 
 
The Work Place Projects did support my belief, molded from my experience in the 
workplace, that for any analysis, a majority of the time is taken up in cleaning data, 
deriving variables needed for the analysis, coding some of the data, writing SAS macros to 
automate some of the repetitive and similar analyses, determining the correct/appropriate 
methods to do the analysis and interpreting the results in the final report.  In contrast very 
little time is spent in actually producing statistical results using statistical software.  To 
produce results that are correct and appropriate, time must be spent on data cleaning and 
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management; to produce results that are meaningful, time must be spent in conceptualizing 
the problem and interpreting the results.  While the coursework for the Masters does help 
one get the skills to determine the appropriate statistical tools necessary for the job and to 
implement the analysis using statistical software, which typically is just a narrow aspect of 
any project, the WPP broadened my skills to include the whole process of carrying out a 
statistical project.   
 
The statistical tools/techniques used for any project must be appropriate for the analyses.  
Thus sometimes, one is required to use tools/techniques that go beyond the scope of one’s 
learning in the coursework component of the Masters course.  Both my projects required 
me to use techniques such as Relative Survival and Standard Incidence Ratios that were 
completely new to me, and techniques such as Survival Analysis with time-varying 
covariates that were not new but that went above and beyond the scope of what I learnt 
during the coursework.  
 
SAS is a powerful and flexible piece of statistical software that allows one to write macros 
to automate some of the tasks one has to do repeatedly.  For example if one has to run a 
Cox regression on a set of variables and then arrange the results in a table in an RTF 
document in a certain way and one has to do this analysis for different sets of variables, one 
can write a macro where one just specifies the set of variables and the macro automatically 
produces the results in a table.  In order to use this powerful macro building feature, I had 
to learn how to analyze survival data using SAS on my own, as STATA was used in the 
coursework.  Also, in order to use SAS to do the analysis I had to spend time arranging the 
data in a way SAS required and deriving certain variables needed by SAS which were 
different from those required for the analysis using STATA.  Although there was a huge 
upfront cost in terms of time spent, the benefits in terms of time saved in using the macros 
multiple times, and the long-term benefits of learning another commonly used software 
package to do the analysis, far outweighed the costs.  
 
Another set of skills that was greatly enhanced by these projects were communication 
skills.  No matter how thoroughly the analyses has been conducted, no matter how 
important the results of the analyses, a lot may be lost if one is not able to communicate the 
results of the analyses in way that is understood by the reader and holds his or her interest.  
 8
One has to build a story, an interesting story; a story in which the objectives are made clear 
to the reader and the reader is lead to the conclusions of the objectives in an orderly way.  
In writing my story I have learnt to think beyond mere technicalities, see things more 
broadly, and be more creative in my story-telling style. 
 
In our modern times in which short but numerous social interactions is such an important 
part of ones lives; times in which these types of social interactions are almost demanded of 
one; times in which one probably is on Face Book and Tweeter and has three or four Instant 
Message accounts besides having an email, SMS and a mobile phone service, it is vitally 
important to have a very specific type of social and inter-relational skill required to meet 
this demand.  My experience in doing the projects has certainly enhanced this skill as I 
have learnt how to write emails that were short (the shortest being a one-word email) and to 
the point, and I learnt how to get the most out of our short but productive meetings we 
would have once every few weeks which were conducted in a friendly manner. 
Ethical considerations 
The registry complies with the Australian Commonwealth Privacy Act governing health 
data collection and maintains patient anonymity by releasing for analysis only de-identified 
data.  Quality control methods for data entry and consistency are routine for all data held in 
ANZDATA, and corrections are also made when inaccuracies are identified when the data 
are used.  The de-identified data was always encrypted and password-protected when not 
being used.   
 
The other datasets used came from the public domain. 
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Location and dates 
School of Public Health, University of Sydney 
August 2008 – June 2009 
 
Context 
Dr. Judy Simpson asked me if I would be interested in doing the two projects in the area of 
End Stage Kidney Disease and working with Dr. Angela Webster and Dr. Patrick Kelly 
who had volunteered to be advisors, to which I answered that I would.  I met with Dr. 
Webster and Dr. Kelly in June of 2008 and they provided me with the dataset and explained 
to me its content.  Dr. Webster also provided me with a few ideas of what specific analyses 
could be done; she also provided me with a few published papers for me to get a few ideas 
from.  I left that meeting knowing that my first step would be to get familiar with the rather 
complicated dataset and also knowing that this project, even though I knew it would be 
about the association between long-term survival and cancer, would be an evolving process.  
In January 2009 at one of my regular meetings with Dr. Angela Webster and Dr. Patrick 
Kelly we discussed ideas of what the second project should be.  In the end we decided that 
although, in Project 1, we did paint a picture of survival for an ESKD patient who had 
cancer who was a child at the onset of the disease, this picture would be complete if we 
could contrast it with the life of similar patients who did not have cancer or did have cancer 
but did not have ESKD.   
 
Student contribution 
I had several meetings with Dr. Webster and Dr. Kelly in which we discussed the analysis 
done so far, the changes to be made to the analysis, the next steps to be taken in the 
analysis, and the appropriate methods needed for the analysis.  The analysis itself was 
carried out by me.    
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Statistical issues 
The main statistical analysis used for this Project 1 was Survival Analysis.  The 
methods/graphs used were Kaplan Meier Survival/Failure curves, Hazard and Cumulative 
Hazard curves, Cox regression with time-varying covariates, and Hazard plots from Cox 
regressions.  A slightly complicated issue was how to model some of the time-varying 
covariates so that the covariates adequately reflected the course over each person’s span of 
time between the onset of ESKD and death or censor.    
 
The statistical tools used for this Project 2 were Standardized Incidence Ratios, 
Standardized Mortality Ratios and Relative Survival.   
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The Story 
 
To give you an idea of the course of life of a patient with ESKD from the onset of ESKD to 
death let us use a fictitious person named Eliss.  Here is her story.  
 
Eliss came into this world sometime in 1981.  She was a happy and healthy little child.  A 
few months after her fifth birthday her parents noticed that Eliss, who rarely made a fuss 
about food, was refusing to eat even her favorite dish which was pasta bolognaise.  They 
also noticed that Eliss, who used to be so cheerful, was becoming increasingly cranky.  
They took her to their local pediatrician to have her checked.  The pediatrician told them 
not to worry as this was possibly just that Eliss had reached a milestone where she was 
asserting her independence.  Just to rule out any other possibility, he took a sample of her 
blood to be tested.  A day later her parents received news that would change their lives 
forever.   
 
The pediatrician called to tell them that Eliss had extremely high levels of creatinine in her 
blood and that they needed to take her immediately to the Children’s Hospital at Westmead 
for further testing.  Eliss was diagnosed with Rapidly Progressive Glomerulonephritis and 
immediately placed under treatment to halt the progress of the disease.  Unfortunately 
nothing could be done and her kidney’s completely failed in a few weeks and she started 
receiving hemodialysis dialysis.  Her parents were completely devastated.   
 
Eliss’s parents attended private information sessions at the Children’s Hospital at 
Westmead with a nephrologist and a counselor.  They both assured the parents that the 
treatment for ESKD had progressed over the decades and it is now quite common for a 
child to lead a relatively full and active life.  However Eliss could be affected both 
physically and psychologically from the disease itself and/or the medication to control the 
disease. The physical conditions could be extreme fatigue, inability to concentrate, weak 
bones, nerve damage, sleep problems, weight gain and delayed growth and development, 
while the psychological problems could include depression and feelings of isolation.   
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They were also informed about their treatment choices which were broadly hemodialysis, 
peritoneal dialysis and transplantation and the risks and benefits of each.  Kidney failure 
can lead directly to more health problems, like swelling of the body, bone deformities, and 
growth failure but a successful kidney transplant could give Eliss the best chance to grow 
normally and lead a relatively normal life.  The donated kidney could come from a recently 
deceased person or a living person, but studies suggest that the graft from a living person 
survives longer.  A donated kidney does not last forever; studies suggest that the median 
survival time of a graft in all children is around 10 to 12 years, but the good news for Eliss 
is that the median graft survival among Asian children in particular was in fact higher.  
Eliss would have to go back on dialysis once the donated kidney failed and while she 
awaited the next donated kidney.  A kidney-transplantation does have elevated risks of 
other diseases associated with it, in particular cancer, and cancer in turn is associated with 
reduced survival.  However studies also suggest that children who are in the five-to-nine-
year age bracket when they start ESKD have a lower risk of acquiring cancer than children 
who are older.  
 
While Eliss awaited her first transplantation she could either continue to receive 
hemodialysis which meant that they would need to bring Eliss to the hospital three or four 
times a week for three to six hour sessions, or she could switch to peritoneal dialysis which 
could be done at home but which needed to be carried out four to five times a day evenly 
spread out and each exchange taking about thirty minutes.  With both types of dialysis Eliss 
would be able to do her homework or watch TV during the procedure.   
 
Eliss’s parents decided to go in for peritoneal dialysis since her mother was a stay-at-home 
parent taking care of Eliss and her younger brother Nick.  Eliss’s mother underwent 
training in how to perform the dialysis procedure.  Eliss would have one dialysis done just 
before she went to school at 8 am, the second one during her lunch break at 12 noon, the 
third one when she came back home from school around 4 pm and the fourth one just 
before she went to bed around 9 pm.  During the non-school days she would keep the same 
time schedule.  Eliss’s school headmistress was most accommodating and made 
arrangement for a small vacant room in the school to be used as her dialysis room which 
was big enough to store the dialysis solution and other equipment and also have a desk and 
a few chairs.   
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Both of Eliss’s parents got themselves tested at the Westmead Hospital to see if they were 
suitable donors.  Eliss’s mother’s kidneys turned out not to be a good match, but fortunately 
for her, her father’s kidneys were a good match.   
 
Around three months after Eliss was first diagnosed with ESKD she was successfully 
implanted with her father’s donated kidney.  She was also put on immunosuppressant drugs 
to stop the immune system from rejecting the donated kidney.  She lived the next few years 
of her life in as normal a way as a child with ESKD could possibly live.   
 
Eliss was now 13 years old and like any teenager would, was worried about her excess 
weight and pale skin colour.   Eliss knew that she had to take the immunosuppressant drugs 
in order for her donated kidney not to be rejected by her body, but also knew that her 
excess weight and pale skin was due to the drugs.  The desire to lose weight overcame her 
and she started skipping doses.  A year later her donor kidney failed and she was put back 
on peritoneal dialysis.   
 
The peritoneal dialysis procedure and the disease itself was crippling her social life as she 
always felt very tired and thus unable to enjoy partying or hanging out with friends for too 
long.  Besides, her tired demeanor made her seem to her friends that she was not really 
interested.  Also, her social life had to be scheduled according to her dialysis schedule; for 
example if she attended any parties she had to make sure she got back home before 9 pm to 
have her dialysis done.   
 
The feeling of guilt at having caused her kidney’s to fail, her crippled social life and her 
feeling of looking ugly because she had put on weight drove her to severe depression.  She 
started spending most of her non-school hours in her room lying in bed.  Her family tried to 
encourage her to socialize with the rest of the family members but she would complain the 
drugs were making her tired and she needed to lie down.   She was less and less inclined to 
go to school and she made all sorts of excuses to skip school.  Once even when her best 
friend Patti came to visit her, Eliss refused to let her into her room.  No amount of 
counseling from the school counselor was having any effect on her.  Her parents grew 
extremely worried and decided to take her to a reputable child psychiatrist who put her on 
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anti-depressives.  After a few weeks on anti-depressives she started feeling better and 
started socializing once again.  From then on the regular intake of anti-depressives became 
an integral part of life.   
 
When she was fifteen years old she received a donor kidney from her dad’s brother.  
Unfortunately her body rejected the graft as soon as it was transplanted.  She went back on 
peritoneal dialysis.  A few months later her doctor gave her the good news that a 
Continuous Cycling Peritoneal dialysis (CCPD) machine was available for her.  This 
machine would automatically empty her abdomen many times at night during sleep and in 
the morning she would just need to do one exchange with a dwell time that lasted the entire 
day.  The switch to CCPD improved her quality of life dramatically.  At school she no 
longer needed to spend her entire lunch break doing her dialysis and could now socialize 
with her friends.  She could stay back after school to cheer on her house’s soccer team or 
attend after-school drama classes, etc.  In the weekends and during school holidays, she 
could hang out with friends the whole day.  She still could not attend school camps or stay 
overnight at a friend’s place or stay partying till late, but she had come to terms with those 
restrictions and felt extremely happy with the freedoms which the CCPD afforded her.   
 
Although she was quite happy with her treatment with CCPD, the doctors advised her to 
take the transplant option when it comes her way as it would increase her life.  At the age of 
18 the transplant option did come her way in the form of a kidney graft from a young man 
who died in a car crash in Parramatta.  Eliss and her parents received a call from Westmead 
Hospital telling them that they had a kidney graft that was a good match and Eliss should 
be brought immediately to the hospital if they wanted the transplant done.   Eliss was very 
uncomfortable about having a dead man’s kidney in her but she did assent to it.  The 
transplant was a successful one.   
 
As part of her treatment for ESKD, Eliss needed to have a blood test done periodically to 
check the progress of the disease and to watch for symptoms of other diseases.  When she 
was 22 years old, one of these blood tests revealed that the white blood cells and platelet 
counts had gone unusually low.  Further testing revealed that she had Leukemia.  The 
oncologist assured Eliss and her parents that the cure rate was quite high for this type of 
Leukemia.  She was treated with pharmaceutical medications which had horrible side-
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effects like nausea, vomiting, diarrhea, poor appetite, and complete hair loss.  However she 
was completely cured in a few months and her hair grew back again.   
 
She was 25 years old when she was last seen at the Westmead Hospital at one of her regular 
visits.   Her doctor noted that she registered low on the depression scale and she reported 
feeling happy and contented in the quality of life questionnaire she filled out.  She had 
experienced terrible misfortunes in her life but she had now reconciled to the fact that 
misfortunes would come her way and was mentally prepared to handle them.  On a poster 
stuck on the door of her room in her family house was printed the immortal words of the 
famous German philosopher Friedrich Nietzsche “That which does not kill us makes us 
stronger”.   
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Overall Aims  
The main aims of Project 1 were to determine if having cancer (before or after the onset of 
ESKD) reduces survival, to specify the main types of cancers that are associated with 
ESKD, to determine the incidence proportion of cancer among ESKD patients, to determine 
the risk factors for getting a cancer after the onset of ESKD, and to determine if cancer 
reduces graft survival. 
 
The main aims of Project 2 were to determine the relative survival of patients with ESKD 
and post-onset cancer and to compare it with the relative survival of patients with ESKD, to 
determine the standardized mortality ratio (SMR) of patients with ESKD and post-onset 
cancer and compare it with the SMR of patient with ESKD, to determine the standardized 
incidence ratio (SIR) of post-onset cancer across subgroups of the ESKD population, and to 
determine the SIR for types of cancers.   
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1. Project 1 
 
Analysis of cancer as a risk factor for survival in patients who 
were under the age of twenty at the onset of ESKD  
 
1.1 Objectives 
There were several objectives for this project.  These objectives are stated below.   
 
 
1. To ascertain the degree of association between cancer and survival in patients with 
ESKD.   
 
2. To provide a descriptions of cancers in patients with ESKD.   
 
3. To ascertain the incidence of cancer during ESKD.   
 
4. To ascertain the risk factors for new cancer during ESKD and their corresponding 
degrees of risk.   
 
5. To ascertain the incidence of a kidney transplant failure.   
 
6. To ascertain the degree of association, if any, between cancer and graft survival.   
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1.2 Data 
This project was a prospective inception-cohort study of all children under the age of 20 
years in the Australia and New Zealand Dialysis and Transplant Registry.  The registry 
collects information about patients receiving renal-replacement therapy who have a 
diagnosis of chronic renal failure and for whom indefinite renal-replacement therapy is 
intended.  These data that is obtained by the registry every six months from all the renal 
units in Australia and New Zealand, is complete from the first use of renal-replacement 
therapy in Australia and New Zealand and includes information on the cause of end-stage 
kidney disease (ESKD), demographic characteristics of the patients, coexisting conditions, 
details of dialysis treatments and renal transplantation, and cause/s of death and past and 
new incidents of cancer diagnoses.   
 
The registry complies with the Australian Commonwealth Privacy Act governing health 
data collection and maintains patient anonymity by releasing for analysis only de-identified 
data.  Quality control methods for data entry and consistency are routine for all data held in 
ANZDATA, and corrections are also made when inaccuracies are identified when the data 
are used.  Further information about ANZDATA can be found by visiting the website 
(ANZDATA, 2009).   
 
All patients in whom renal replacement therapy started in Australia or New Zealand 
between 1st of January 1963 and 31st December 2006 and who were registered in the 
ANZDATA registry and who were under the age of 20 when this therapy began are 
included in the study.  These patients were followed until death or 31st December 2006, 
whichever occurred earlier.  Two patients who made a temporary recovery of renal function 
were excluded from the dataset.  There were 1930 patients in the dataset.   
 
All the analysis was done using this registry data and these data only. 
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Inclusion criteria 
 
The following is the inclusion criteria for this project: 
 
• Residents of Australia or New Zealand 
• Renal replacement therapy started in Australia or New Zealand between 1st of January 
1963 and 31st December 2006 
• Under the age of 20 when renal replacement therapy began 
 
 
Restructuring of data and deriving variables 
 
The analysis required the data to be restructured and variables to be described.  Two data 
sets were created: one dataset had just one record per person and the other dataset had for 
those people who got a cancer one record for every cancer they got and for those who did 
not have a cancer one record per person.  
 
The following is a list of the data manipulations done: 
 
1. Certain non-cancers which were coded as cancers had to be deleted.  Certain cancer 
related primary renal disease was in free text; these needed to be coded and brought into 
the primary disease field.  Two or more cancers for each person could have the same 
exact date and this could have caused issues with the analyses and so in these cases a 
small amount of time was added to the later cancer/s so that the order of the cancers 
was maintained.  A variable was created to determine whether the cancer was pre or 
post onset of ESKD.  The number of pre and post onset of ESKD cancers had to be 
determined for each patient.  A pre-first transplant cancer flag was derived which took 
the value 1 if a person did have a cancer and his or her cancer date was before the first 
transplant date and zero otherwise.  For some of the analysis we needed to track in 
which period the cancer happened, i.e. did it happen in the first transplant period, or in 
the dialysis period straight after the first transplant period, etc.  We created three 
variables for the first, second and third post-onset of ESKD cancer a person could 
possibly get and each of these variables took on the integers 1 to 10 with 1 being if the 
cancer fell in the period D1 (dialysis before the first transplant), 2 being if the cancer 
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fell in the period T1 (first transplant period), 3 being if the cancer fell in the period D2 
(dialysis after first transplant), 4 being if the cancer fell in the period T2 (second 
transplant period), etc.   
 
2. The variables age and age group at the onset of ESKD were derived.  Age at onset of 
ESKD was derived by using the formula (first renal replacement therapy date – date of 
birth)/365.25.  A categorical variable age group at onset of ESKD was created by 
dividing this age into five groups, i.e. < 1 years, 1-4 years, 5-9 years, 10-14 years,15-19 
years.  The variables age and age group at the first kidney transplant were derived.  Age 
at first kidney transplant was derived by using the formula (first kidney transplant date 
– date of birth)/365.25.  A categorical variable age group at first kidney transplant was 
created by dividing this age into five groups, i.e. < 4 years, 5-9 years, 10-14 years, 15-
19 years, > 19 years.   
 
3. The dataset had the first RRT date, transplant dates and transplant periods.  Thus the 
dialysis dates had to be derived from this information.  For example the start of the 
dialysis period after the first transplant failure would be the first transplant date plus the 
first transplant period, but only if the calculated date was not equal to the death date.  
The duration of each dialysis period had to be calculated.  For example the duration of 
the first dialysis could be the first transplant date minus the first RRT date plus one; but 
if the person did not have a transplant then it would be the death date minus the first 
RRT date plus one; but if the person’s first RRT date was a transplant then the person is 
stated to have not had a first dialysis.   
 
4. Some duration variables for the survival analyses had to be derived:  
• Period from ESKD to death or censoring which is calculated as death date minus 
first RRT date plus 1 
• Period form ESKD to first cancer was calculated as first cancer date minus first 
RRT date 
 
5. Era (1963-79, 1980-89, 1990-99, 2000-06) of first RRT had to be derived from the first 
RRT date.  Race which was categorized in very narrow bands in the original data had to 
be collapsed into three broad categories: Caucasian, Indigenous & Pacific Islanders, and 
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Asians.  Place of residence which was in very narrow bands in the original data had to 
be collapsed into three places: Australia, New Zealand, and overseas (and not NZ).  
‘Donor type’ variable i.e. whether the donor was the sister, brother, mother, father, non-
related, etc., which had narrow bands in the original data had to be collapsed into two 
categories: living (related or non-related) and deceased (related or non-related).  The 
Cause of Death (from death registry) which were in narrow bands had to be collapsed 
into seven broad categories: cardiac, infection, vascular, treatment withdrawal, cancer, 
suicide/accident and other.  The ‘primary renal disease’ (primary cause of renal disease) 
field which was in narrow bands had to be collapsed seven broad categories: 
Glomerulonephritis, reflux, congenital/urological, cystic/hereditary, interstitial 
nephritis, cancer related, and other/uncertain. 
 
6. Two binary variables and two period variables were created for the first and second 
cancer that started while the person had his/her first donor graft in him.  These variables 
had to be created very carefully since the first cancer could possibly have started before 
the first transplant, in which case the second cancer would have to be checked to see if 
it fell during the first graft survival period and coded as the first post-first transplant 
cancer; etc. Similarly the time period from the first transplant date to the first post-
transplant cancer date could possibly be the date from the first transplant date to the 
second cancer date if the first cancer date was before the first transplant date, etc.   
 
7. A censor variable needed to be created for the ‘time to first transplant failure’ analysis.  
This variable was a binary variable which took the value 1 if either the person had a 
more than one graft transplant over his or her period of observation or if he or she had 
just one graft then only if the there was a dialysis period after the first transplant period.  
Else the variable was given the value 0 but only if the number of grafts was greater than 
zero; if it was zero then the variable would take on a missing value.  A censor variable 
needed to be created for the ‘time to first cancer’ analysis.  This binary variable took on 
the value 1 if the first cancer date was not missing and zero otherwise.   
 
8. To calculate the incidence of cancer in each treatment period i.e. the incidence of cancer 
in the dialysis period just before the first transplant (D1), the first transplant period 
(T1), the dialysis period just after the first transplant (D2), etc.  we needed to get the 
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total number of first cancers in each of the treatment periods D1, T1, D2, etc.  In order 
to calculate the incidence of the first cancer in each period we needed to calculate the 
number of person-years in each period.  We calculated each person contribution of 
person years by first determining which period the person’s first cancer fell into e.g. T1.  
Then the person’s contribution to person years for that period would be from the date of 
his/her first cancer to the date when the first graft failed.  His/her contribution to the 
other periods would be zero.   
 
9. The cancers had to be described.  The first step was collecting all the cancers which 
were in four separate fields (cancer site code and free text, cancer type code and free 
text), and bringing them together.  The next step was to classify the cancer according to 
area e.g. digestive and cancer site e.g. pancreas, which was compatible to be coded 
using the ICD10 coding system.  The next step was to give each cancer a specific 
ICD10 code. 
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2. Patient Characteristics 
2.1 Description of Patient Characteristics 
Table 2.1 proved some information regarding the distribution of the patients in our study 
over gender, race, etc, and by five age categories, the age categories being based on the age 
at the onset of ESKD.  There were more males than females whose onset of ESKD began at 
a very young age; 74% of the infants and 61% of the 1 to 4 year olds who were diagnosed 
with ESKD were males.  Almost 40% of the infants and 49% of the 1 to 4 year olds had 
Congenital/Urological as their primary disease category; about 50% of the 15 to 19 year 
olds had Glomerulonephritis as their primary disease category.   
 
Peritoneal dialysis was the most commonly used first Renal Replacement Therapy (RRT) 
among the patients who were under the age of 15 at the onset of ESKD with almost 92% of 
the infants and 68% of the 1 to 4 year olds receiving that treatment whereas hemodialysis 
was more commonly used as the first RRT among patients who were 15 years and older at 
the onset of ESKD with 65% of the 15 to 19 year olds receiving that treatment; only about 
10% of the patients received a transplant as his/her first RRT.  The first kidney graft for 
children who were young at the onset of ESKD most often came from a living donor with 
almost 48% of the infants and 59% of the 1 to 4 year olds receiving it from a living donor; 
the first kidney graft for children who were older at the onset of ESKD most often came 
from a deceased donor with 58% of the 15 to 19 year olds receiving it from a deceased 
donor.  Nearly 61% of the patients received at least one kidney graft and there were 28 
patients who receiving four grafts and one patient who received five graft over the period of 
observation.   
 
In the period 1963 to 1979, out of the 415 patients diagnosed with ESKD there were no 
infants diagnosed and only five 1 to 4 year olds.   About 28% of the patients died during the 
period of observation and this percentage was fairly evenly distributed across the age 
group.  The most common cause of death was cardiac failure 33% of the patients dying 
from it; the most common cause among patients who were young children at the onset of 
ESKD was infection with it accounting for 40% of the deaths among infants and 53% of the 
deaths among the 1 to 4 year olds; cancer was the cause of 7% of the deaths with children 
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whose onset of ESKD began at the ages of 10 to 19 years being most effected.  110 patients 
or 6% of the patients in our study were diagnosed with a cancer after the onset of ESKD out 
of which 99 patients were between the ages of 10 to 19 years old at the onset of ESKD.   
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Table 2.1 Description of Patient Characteristics 
 Age Groups at the onset of ESKD   
Age group at the onset of ESKD <1 
46 
1 to 4 
147 
5 to 9 
281 
10 to 14 
484 
15 to 19
972 
Overall 
1930 
  n (%) n (%) n (%) n (%) n (%) n (%) 
Gender Female 12 (26.1) 57 (38.8) 125 (44.5) 224 (46.3) 436 (44.9) 854 (44.2) 
 Male 34 (73.9) 90 (61.2) 156 (55.5) 260 (53.7) 536 (55.1) 1076 (55.8) 
Race Caucasians 43 (93.5) 129 (87.8) 236 (84) 407 (84.1) 809 (83.2) 1624 (84.1) 
 Indigenous and Pacific 
Islanders 
2 (4.3) 7 (4.8) 31 (11) 54 (11.2) 118 (12.1) 212 (11) 
 Asians 1 (2.2) 11 (7.5) 14 (5) 23 (4.8) 45 (4.6) 94 (4.9) 
Primary Disease 
category 
Glomerulonephritis 1 (2.2) 18 (12.2) 67 (23.8) 152 (31.4) 487 (50.1) 725 (37.6) 
 Reflux 1 (2.2) 6 (4.1) 33 (11.7) 116 (24) 233 (24) 389 (20.2) 
 Congenital/Urological 20 (43.5) 72 (49) 70 (24.9) 106 (21.9) 95 (9.8) 363 (18.8) 
 Cystic/Hereditary 3 (6.5) 8 (5.4) 46 (16.4) 65 (13.4) 45 (4.6) 167 (8.7) 
 Interstitial Nephritis 1 (2.2) 0 5 (1.8) 4 (0.8) 15 (1.5) 25 (1.3) 
 Cancer related 2 (4.3) 4 (2.7) 3 (1.1) 1 (0.2) 2 (0.2) 12 (0.6) 
 Other/Uncertain 18 (39.1) 39 (26.5) 57 (20.3) 40 (8.3) 95 (9.8) 249 (12.9) 
First treatment 
group 
Hemodialysis 4 (8.7) 11 (7.5) 53 (18.9) 175 (36.2) 633 (65.1) 876 (45.4) 
 Peritoneal Dialysis 42 (91.3) 112 (76.2) 190 (67.6) 244 (50.4) 280 (28.8) 868 (45) 
 Transplant 0 24 (16.3) 38 (13.5) 65 (13.4) 59 (6.1) 186 (9.6) 
Country of 
residence at the 
first RRT 
Australia 37 (80.4) 126 (85.7) 224 (79.7) 385 (79.5) 748 (77) 1520 (78.8) 
 New Zealand 9 (19.6) 19 (12.9) 55 (19.6) 95 (19.6) 207 (21.3) 385 (19.9) 
 Overseas 0 2 (1.4) 2 (0.7) 4 (0.8) 17 (1.7) 25 (1.3) 
First donor Deceased donor 10 (21.7) 40 (27.2) 123 (43.8) 253 (52.3) 563 (57.9) 989 (51.2) 
 Living donor 22 (47.8) 86 (58.5) 131 (46.6) 189 (39) 264 (27.2) 692 (35.9) 
Maximum number 
of transplants 
received by any 
patient 
0 14 (30.4) 21 (14.3) 27 (9.6) 42 (8.7) 142 (14.6) 246 (12.7) 
 1 30 (65.2) 102 (69.4) 188 (66.9) 287 (59.3) 560 (57.6) 1167 (60.5) 
 2 2 (4.3) 19 (12.9) 57 (20.3) 110 (22.7) 205 (21.1) 393 (20.4) 
 3 0 5 (3.4) 6 (2.1) 34 (7) 50 (5.1) 95 (4.9) 
 4 0 0 3 (1.1) 11 (2.3) 14 (1.4) 28 (1.5) 
 5 0 0 0 0 1 (0.1) 1 (0.1) 
Era of first 
treatment 
1963 to 1979 0 5 (3.4) 45 (16) 111 (22.9) 254 (26.1) 415 (21.5) 
 1980 to 1989 4 (8.7) 32 (21.8) 75 (26.7) 154 (31.8) 275 (28.3) 540 (28) 
 1990 to 1999 24 (52.2) 65 (44.2) 82 (29.2) 140 (28.9) 250 (25.7) 561 (29.1) 
 2000 to 2006 18 (39.1) 45 (30.6) 79 (28.1) 79 (16.3) 193 (19.9) 414 (21.5) 
Last known 
outcome 
Alive Dec 2006 31 (67.4) 113 (76.9) 210 (74.7) 339 (70) 645 (66.4) 1338 (69.3) 
 Dead 15 (32.6) 32 (21.8) 65 (23.1) 132 (27.3) 302 (31.1) 546 (28.3) 
 Lost 0 2 (1.4) 6 (2.1) 13 (2.7) 25 (2.6) 46 (2.4) 
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Table 2.1 Description of Patient Characteristics (continued)  
Patients with at 
least one pre-ESKD 
cancer 
 0 4 (2.7) 5 (1.8) 2 (0.4) 5 (0.5) 16 (0.8) 
Patients with at 
least one post-
ESKD cancer 
 3 (6.5) 4 (2.7) 4 (1.4) 25 (5.2) 74 (7.6) 110 (5.7) 
 
Table 2.1(b) Description of Patient Characteristics (with number of deaths as 
denominator) 
 
 Age Groups at the onset of ESKD  
Age group at the onset of ESKD <1 1 to 4 5 to 9 10 to 14 15 to 19 Overall 
  n (%) n (%) n (%) n (%) n (%) n (%) 
Cause of death Cardiac 5 (33.3) 6 (18.8) 20 (30.8) 34 (25.8) 113 (37.4) 178 (32.6) 
 Infection 6 (40) 17 (53.1) 8 (12.3) 19 (14.4) 61 (20.2) 111 (20.3) 
 Vascular 0 1 (3.1) 12 (18.5) 21 (15.9) 30 (9.9) 64 (11.7) 
 Treatment Withdrawal 3 (20) 5 (15.6) 13 (20) 17 (12.9) 25 (8.3) 63 (11.5) 
 Cancer 0 1 (3.1) 2 (3.1) 13 (9.8) 23 (7.6) 39 (7.1) 
 Suicide/Accident 0 1 (3.1) 2 (3.1) 8 (6.1) 13 (4.3) 24 (4.4) 
 Other 1 (6.7) 1 (3.1) 8 (12.3) 20 (15.2) 37 (12.3) 67 (12.3) 
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2.2 Duration of dialysis and transplant periods and incidence of cancer 
in each period 
 
Table 2.2 provides summary statistics about the time at each stage of treatment i.e. time on 
dialysis before first transplant, time on first transplant, etc. and the incidence of cancer at 
each stage of treatment.  This analysis provides an exploratory look at a possible 
association between cancer and type of treatment (dialysis or transplant).   
 
From Table 2.2 we see that persons differed considerably in terms of the duration of 
dialysis and transplant with the average difference in duration among them being nearly as 
much as the average duration itself.  On average, the first and second transplants survived 
for seven years with 25% surviving for more than 11.7 years and 9.9 years for the first and 
second donor graft respectively; these are underestimations as we have not accounted for 
censoring here.  The duration of the dialysis before the first transplant was short with an 
average of just 1.7 years but the duration of the later dialysis getting progressively longer 
with the duration of the dialysis after the third transplant being nearly six years; possibly 
reflecting the increasing difficulty of getting a kidney donor graft.  Sixty percent of the 110 
post onset of ESKD cancers started during the first transplant period and 20% occurred 
during the second transplant.  The first transplant period, the second transplant period, and 
the period on dialysis just after the third transplant had incidence rates of cancer that were 
above five per 1000 patient years. 
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Table 2.2 Duration of dialysis and transplant and the incidence of cancer in each 
treatment period 
 Duration of treatment (in years) Incidence of cancer  
Treatment period Mean (SD) Median [Q1 - Q3] 
Patient 
years 
Number of 
cancers 
Incidence 
(per 1000 
patient 
years) 
D1 - Dialysis before first transplant if any 1.7 (2.43) 0.9 [0.3 - 2.1] 3209 6 1.87 
T1 - First transplant 7.7 (7.66) 5.3 [1.5 - 11.7] 12551 66 5.26 
D2 - Dialysis just after first transplant 3.4 (3.81) 2.1 [0.9 - 4.4] 2586 9 3.48 
T2 - Second transplant 6.5 (7.02) 4.2 [0.5 - 9.9] 3254 20 6.15 
D3 - Dialysis just after second transplant 4.9 (5.35) 3.2 [1.1 - 6.6] 1189 5 4.21 
T3 - Third transplant 5.4 (5.91) 2.8 [0.4 - 8.7] 645 2 3.10 
D4 - Dialysis just after third transplant 5.9 (5.96) 3.3 [1.6 - 8.3] 353 2 5.67 
T4 - Fourth transplant 5.7 (7.22) 2.4 [0.6 - 8.9] 165 0 0 
D5 - Dialysis just after fourth transplant 3.4 (3.05) 2.1 [1.4 - 7.3] 34 0 0 
T5 - Fifth transplant 4.9 (n/a)* 4.9 [4.9 - 4.9] 5 0 0 
Note: The duration in each period and the number of cancers could be an underestimation because we have 
not accounted for the time to death beyond 31 December 2006.   
*No SD because there is only one patient 
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2.3 Distribution of Cancers by Cancer Site 
Table 2.3.1 provides a frequency distribution of the pre-onset-of-ESKD diagnosed cancer 
patients across cancer sites.  Sixteen patients had a cancer before being diagnosed for 
ESKD out of whom 9 patients had cancer in the kidney area.   
 
Table 2.3.1 Distribution of pre-onset-of-ESKD Diagnosed Cancer patients 
 Cancer Site 
ICD 
Codes 
N=16 
n(%) 
Any  C00-C95 16 (100) 
Reproductive and genitourinary   9 (56) 
 Kidney (non-transplanted) C64 9 (56) 
Endocrine   3 (19) 
 Adrenal gland C74 3 (19) 
Hematological   4 (25) 
 Hodgkin disease C81 1 (6) 
 Leukemia C91-C95 2 (13) 
 Non-Hodgkin lymphoma C82-C85 1 (6) 
 
Table 2.3.2 provides a frequency distribution of the patients that had newly diagnosed 
cancers during ESKD.  One hundred and ten patients had a cancer during the period of 
observation.  Patients with cancers associated with the reproductive and genitourinary 
system and hematological system accounted for 67% of the patients, with the 
skin/connective tissue and digestive systems accounting for a further 26%.  Nearly 30% of 
the patients had a Lymphoma related cancer. 
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Table 2.3.2 Distribution of post-onset-of-ESKD Diagnosed Cancer patients 
 Cancer Site 
ICD 
Codes 
N=110 
n(%) 
Any  C00-C95 110 (100)
Lip and oral cavity   4 (4) 
 Mouth C03-C06 2 (2) 
 Salivary gland C07-C08 1 (1) 
 Tonsil C09 1 (1) 
Digestive   16 (15) 
 Anus C21 4 (4) 
 Colon C18 3 (3) 
 Esophagus C15 1 (1) 
 Gallbladder C23-C24 4 (4) 
 Liver C22 1 (1) 
 Pancreas C25 1 (1) 
 Rectum C19-C20 1 (1) 
 Stomach C16 1 (1) 
Respiratory and intra-thoracic   1 (1) 
 Trachea, bronchus, and lung C33-C34 1 (1) 
Skin/connective tissue   13 (12) 
 Connective and other soft 
tissue 
C47-C49 1 (1) 
 Kaposi sarcoma C46 2 (2) 
 Melanoma C43 10 (10) 
Reproductive and genitourinary   36 (33) 
 Breast C50 1 (1) 
 Kidney (non-transplanted) C64 7 (6) 
 Kidney (transplanted) C64 6 (6) 
 Ovary C56 1 (1) 
 Penis C60 1 (1) 
 Testis C62 3 (3) 
 Uteri cervix C53 8 (7) 
 Uterus C54 2 (2) 
 Vagina C52 2 (2) 
 Vulva C51 6 (6) 
Neurological   3 (3) 
 Brain C71 1 (1) 
 Meninges C70 2 (2) 
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Table 2.3.2 Distribution of post-onset-of-ESKD Diagnosed Cancer patients 
(continued) 
Endocrine   6 (6) 
 Thyroid C73 6 (6) 
Hematological   38 (35) 
 Hodgkin disease C81 3 (3) 
 Leukemia C91-C95 3 (3) 
 Non-Hodgkin lymphoma C82-C85 15 (14) 
 Lymphoproliferative disease  17 (16) 
Unknown/other   3 (3) 
 Unknown/other  3 (3) 
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3.  Time to First Cancer 
3. 1 Incidence of post-onset-of-ESKD Cancer 
In this section we provide the incidence proportion of cancer as a continuous function of 
time using the Kaplan-Meier (KM) Failure Curve for Time to First post-ESKD Cancer 
[Please see Appendix 1.1 for a definition and formula of the KM estimator].  Using a KM 
curve to calculate the incidence proportion was quite necessary here as there were, 
expectedly, a large number of censored observations.  The total analysis time at risk for 
post-onset-of-ESKD cancer was 23,989 years for the 1,930 subjects we have in our data 
and 110 subjects were diagnosed with post-onset-of-ESKD cancer.  Thus the incidence rate 
was 4.59 per 1000 patient years.   
 
Figure 3.1.1 provides us with incidence proportion as a continuous function of time.  The 
incidence proportion is defined here as the proportion of ESKD patients acquiring cancer.  
The graph shows that over a five year period from the onset of ESKD the incidence 
proportion was 1.25%, over a ten year period it was 3.5%, over a 15 year period it was 
6.25%, and over a 20 year period it was 8%.  There is a high initial hazard of getting a 
cancer in the first year after the onset of ESKD.  This incidence proportion then increases at 
an increasing rate till 10-12 years and then increases at a constant rate.   
 
Figure 3.1.1 Kaplan-Meier Failure Curve  
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From Figure 3.1.2 we see that the hazard of acquiring a new cancer increases till around 12 
years post-onset of ESKD and then remains constant. 
 
Figure 3.1.2 Smoothed Hazard Estimate  
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The Epanechnikov Kernel function is used to smooth the hazard estimate 
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3.2 Identifying the risk factors for post-onset-of-ESKD cancer 
 
A Cox Proportion Hazards model was fitted with dependent variable for the model being 
‘time to first cancer since the onset of ESKD’.  The covariates considered (deemed to be 
clinically important and based on the variable in the ANZDATA) for our model were 
gender, race, age group at onset of ESKD, treatment type, state of residence at the first 
renal replacement therapy, era of first treatment and primary disease category.  ‘Treatment 
type’ was a time-varying variable that has the value 1 only for the time period after the 
person had his/her first transplant and 0 otherwise. (See Appendix 1.2 for description of the 
covariates). 
 
A Proportional Hazards model was built using the model building process as prescribed by 
Hosmer et al (2008).  The first step was to choose all covariates significant at the 25% level 
from a univariable analysis as well as those covariates deemed to be clinically significant.  
The initial multi-variable model was simplified by excluding variables that were not 
significant at the 5% level (starting with the covariate with the largest p-values) but testing 
if the excluded variable/s were important confounders (considered important if they change 
the coefficients of the existing variables by more than 20%).  In the next step we added 
back, one at a time, the variables that did not meet the criteria of 25% in the univariable 
analysis.  All tests were done using the Wald test. 
 
 
The model is checked for strong violations of the proportion hazards assumption by the 
non-time-dependent covariates.  We shall use a test based on the Schoenfeld residuals; the 
idea is to retrieve the residuals, fit a smooth function of time to them, and then test whether 
there is a relationship. We shall not make any modifications to our model if the proportion 
hazards assumption was not severely violated (p-value of global test ≥ 0.01) as it would just 
mean that we may not have modeled a weak but statistically significant interaction with 
time and thus have an average effect over the observed time.  We choose a p-value of less 
than 0.01 because the number of events is large and so the tests of the PH assumption are 
quite sensitive to small violations in the assumption.  If, however, the PH assumption was 
strongly violated then we shall refit the model by taking into account this interaction with 
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time.  In the last step of our model building process we shall estimate our model and do 
post-hoc estimation of orthogonal contrasts. 
 
Table 3.2.1 shows the results of the univariable analysis.  Based on the overall p-value, the 
covariates chosen were race, age group, era of first treatment and treatment type.   
 
Table 3.2.1 Univariable Analysis for Time to First Cancer (after onset of ESKD) 
Covariate 
Reference 
Level Level 
Hazard 
Ratio 
HR 
LCL 
HR 
UCL 
Overall 
P-value 
Gender Female Male 0.93 0.64 1.35 0.690 
Race Caucasians Indigenous and Pacific 
Islanders 
0.37 0.12 1.16 0.229 
  Asians 0.89 0.28 2.82  
Primary Disease 
category 
Glomerulonephritis Cystic/Hereditary 0.74 0.35 1.57 0.383 
  Reflux 0.87 0.55 1.37  
  Interstitial Nephritis 1.62 0.39 6.66  
  Congenital/Urological 0.65 0.36 1.17  
  Cancer related 0.00 0.00 .  
  Other/Uncertain 0.39 0.16 0.98  
Age group at onset of 
ESKD 
5 to 9 years < 1 years 11.32 2.52 50.85 0.006 
  1 to 4 years 2.73 0.68 10.92  
  10 to 14 years 3.03 1.05 8.71  
  15 to 19 years 4.50 1.64 12.31  
State of residence at 
the first RRT 
Australia New Zealand 0.96 0.58 1.57 0.976 
  Overseas 0.86 0.12 6.18  
Era of first treatment 1980 to 1989 1963 to 1979 1.32 0.81 2.15 0.206 
  1990 to 1999 1.55 0.91 2.65  
  2000 to 2006 2.38 0.94 6.03  
Treatment Type Dialysis Transplant 1.87 1.14 3.06 0.013 
 
Table 3.2.2 shows the results of fitting a multivariable model using the covariates chosen in 
the univariable analysis.  Instead of using the binary time varying covariate for ‘treatment 
type’ we used a categorical time varying variable which provided us more information 
regarding differences in transplant and dialysis periods.  This covariate had the value 1 for 
when the person was on dialysis just before the first transplant (D1), 2 for when she was on 
her first transplant (T1), 3 for when she was on dialysis just after the first transplant (D2), 4 
for when she was on her second transplant (T2), 5 when she was on any dialysis after the 
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second transplant (D3+) and 6 when she was on any transplant after the second transplant 
(T3+).   
 
Looking at the overall p-values we saw that race and ‘era of first treatment’ were the only 
two covariates that did not seem to be significant at the 5% level.  Confounding was 
checked by dropping the two covariates from the model, running the regression and seeing 
if that changes the coefficients of the remaining covariates by more than 20%.  Our check 
revealed that they were not important confounders and so they were dropped permanently 
from our model.   
 
We next added back, one at a time, the variables that did not meet the criteria of 25% in the 
univariable analysis.  The variables added back one at a time were pre-cancer flag, gender, 
state of residence at the first RRT, and primary disease category.   None of the excluded 
variables were significant and so they were dropped permanently from the model.  
 
We tested whether the different dialysis periods had equal risks and similarly whether the 
different transplant periods had equal risks.  If the transplant periods had equal risk then we 
would create one covariate for transplant period.  D2 risk was compared to D3+ risk to see 
if there was a significant difference; if there was then we look at a comparison of the two 
combined (D2 + D3+) versus D1 and if this was also not significant then we would merge 
them into one.  If both, dialysis periods and transplant periods were not different, then we 
would revert back to our binary covariate for dialysis versus transplant.  From Table 3.2.3 
we see that the transplant periods had equal risk and the dialysis periods had equal risks.  
Thus we had only one time-varying binary covariate which took the value 1 when the 
person was on transplant and 0 otherwise.   
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Table 3.2.2 Initial Multivariable Analysis  
Covariate 
Reference 
Level Level 
Hazard 
Ratio 
HR 
LCL 
HR 
UCL 
Overall
P-value
Race Caucasians Indigenous and Pacific 
Islanders 
0.45 0.14 1.45 0.410 
  Asians 0.97 0.30 3.12  
Age group at onset of ESKD 5 to 9 years < 1 years 10.41 2.29 47.43 0.004 
  1 to 4 years 2.36 0.59 9.49  
  10 to 14 years 3.20 1.11 9.22  
  15 to 19 years 4.89 1.78 13.44  
Era of first treatment 1980 to 1989 1963 to 1979 1.16 0.71 1.89 0.184 
  1990 to 1999 1.58 0.91 2.73  
  2000 to 2006 2.50 0.98 6.41  
Treatment Type D1: Dialysis just 
before first 
transplant 
T1: 1st Tx  4.09 1.54 10.81 0.045 
  D2: Dx just after 1st Tx  2.82 0.87 9.06  
  T2: 2nd Tx  3.96 1.32 11.89  
  D3+: All Dx after 2nd Tx  2.92 0.84 10.21  
  T3+: 3rd or higher Tx  1.35 0.24 7.56  
 
Table 3.2.3 Tests for the equality of the dialysis and transplant periods 
Linear Test 
Wald 
ChiSq DF P-Value
T1=T2=T3+:    Transplant treatments periods have equal risk 2.577 2 0.276 
D2=D3+:         Dx just after 1st Tx risk = All Dx after 2nd Tx risk  0.007 1 0.933 
D2+D3+ = 0:   Dx just after 1st Tx + All Dx after 2nd Tx is significantly    
                        different from Dx just before 1st Tx 
3.297 1 0.069 
 
We next fitted the model and tested the proportional hazards assumption.  Table 3.2.4 
shows the results of the test.  We see that the global test showed non-significance and we 
also see that none of the time-constant covariates had a significant p-value.  Thus we do not 
modify the model.   
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Table 3.2.4 Test of the Proportional Hazards Assumption 
  Rho ChiSq DF Prob>ChiSq
Age group 
(years): 
 <1 -0.02239 0.06 1 0.814 
1 to 4 -0.06666 0.49 1 0.4859 
10 to 14 0.00017 0 1 0.9985 
15 to 19 -0.05769 0.37 1 0.5429 
Treatment Type -0.26314 8.59 1 0.0034 
Global test   10.86 5 0.0543 
 
Table 3.2.5 presents the results of fitting the final model in which we see that, among the 
covariates considered for our model, the only two covariates that were significantly 
associated with time-to-first-post-onset-of-ESKD-cancer were ‘age-group at the onset of 
ESKD’ and ‘type of treatment’.   
 
 In Table 3.2.6 we present post-estimation orthogonal contrast which gives us estimations 
of important pair-wise comparisons.  The hazard of getting a cancer for the less-than-one-
year-olds was 4.3 times (95% CI: 0.97-19.5) that of the one-to-four-year-olds, 11.5 times 
(95% CI: 2.6-51.4) that of the five-to-nine-year-olds, just under 3.8 times (95% CI: 1.1-
12.4) that of the ten-to-fourteen- year-olds, and no different from that of the fifteen-to-
nineteen-year-olds.  The hazard for the five-to-nine-year-olds was about a third (95% CI: 
0.11-0.93) the hazard of the ten-to-fourteen- year-olds and about a fifth (95% CI: 0.08-
0.59) of the hazard of the fifteen-to-nineteen-year-olds.  
 
The hazard of getting a cancer when one was on a transplant was 1.9 times (95% CI: 1.2-
3.2) the hazard of getting a cancer when one was on dialysis.  Thus being on a transplant 
almost doubled ones risk of acquiring cancer.   
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Table 3.2.5 Final Multivariable Analysis for Time to First Cancer (Post-Onset of 
ESKD) 
Covariate 
Reference
Level Level 
Hazard
Ratio 
HR
LCL
HR 
UCL 
P-
value 
Overall 
P-value 
Age group at onset 
of ESKD 
5 to 9 < 1 11.47 2.56 51.43 0.012 0.005 
  1 to 4 2.64 0.66 10.55 0.572  
  10 to 14 3.08 1.07 8.86 0.721  
  15 to 19 4.63 1.69 12.67 0.132  
Treatment Type Dialysis Transplant 1.94 1.18 3.20 0.009 0.009 
 
 
Figure 3.2.1 presents the hazard of cancer by treatment type derived after estimating a Cox 
model.  We see that the hazard for a patient during any transplant period was higher that in 
any dialysis period.    
 
Figure 3.2.2 presents the hazard of cancer for the different age groups by treatment derived 
after estimating a Cox model.  We see that the hazard of a cancer for a patient during any 
kidney transplant period was higher than in any dialysis period for all age groups except 
possibly for the five-to-nine age group for whom it seemed to be equal.  We see that the 
less-than-one-year-olds had a much higher hazard of getting a cancer than the rest of the 
age-groups.  Also, among the less-than-one-year-olds, the hazard of cancer during any 
transplant period was much higher than during any dialysis period.  Taken together this 
implies that the less-than-one-year-olds with a transplant were at the highest risk of 
acquiring cancer.   
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Figure 3.2.1 Hazard of Cancer from Transplant or Dialysis   
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Figure 3.2.2 Hazard of Cancer for the different age groups by type of treatment 
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4. Time to First Kidney Transplant Failure 
4.1 Incidence of First Kidney Transplant Failure 
In this section we provide the incidence proportion of first kidney transplant failure as a 
continuous function of time using the Kaplan-Meier Failure Curve for Time to First Kidney 
Transplant Failure.  The analysis variable here was ‘time to first kidney transplant failure 
from the date of first transplant’.  Out of the 1930 subjects in our study, 246 did not have a 
kidney transplant.  The total analysis time for the remaining 1,684 subjects was 12,890.67 
years and the number of subjects who had a transplant failure was 812.  Thus the incidence 
rate was 63 per 1000 patient-years.   
 
Figure 4.1.1 provides us with incidence proportion as a continuous function of time.  The 
incidence proportion is defined here as the proportion of ESKD patients with a first kidney 
graft whose graft failed.  Over a five year period from the date of the transplant the 
incidence proportion was 40%, over a ten year period it was 48%, over a 15 year period it 
was 60%, and over a 20 year period it was 65%.  We see that there was a steep drop in 
survival at the very beginning of nearly 12% which includes grafts that were rejected 
straight after being transplanted; the incidence proportion then increases linearly over time.   
 
Figure 4.1.1 Kaplan-Meier Survival Curve  
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From Table 4.1.1 we see that the median survival time for a first graft was 11.77 years 
(10.5, 12.8).  At 3.2 years 75% of the first grafts had not failed and at 28.2 years 25% of the 
first grafts had not failed.   
 
Table 4.1.1 Quartiles of Survival Time 
      Survival Times (in years)   
Time at 
Risk 
Incidence 
Rate 
No. of 
subjects 25% 50% 75% 
95% CI 
50% Survival 
12891 0.063 1684 3.22 11.76 28.22 (10.54, 12.79) 
 
In Figure 4.1.2 we see that the hazard of a transplant failure increased in the first year and 
then was relatively constant over the remaining life of the first kidney graft.    
 
Figure 4.1.2 Smoothed Hazard Estimate of a First Kidney Graft Failure 
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The Epanechnikov Kernel function is used to smooth the hazard estimate 
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4.2 Identifying the risk factors for a first kidney transplant failure 
A Cox Proportional Hazards model was fitted with the outcome variable being ‘time to first 
kidney transplant failure from the date of first transplant’.  The covariates considered for 
our model were first post-first transplant cancer,  age-group at first transplant, duration of 
the first dialysis, gender, race, primary disease category, state of residence at the first renal 
replacement therapy, first donor type and era of first treatment.  The ‘first post-first 
transplant cancer’ was a binary time-varying covariate which took on the value 1 from the 
time during the life of the first kidney graft when the person was diagnosed with cancer and 
zero at all other times.  (See Appendix 1.3 for description of the covariates). 
 
Since we were interested in estimating the additional effect of cancer adjusting for other 
covariates, we excluded the cancer variables from the variable selection process and 
brought them in after the preliminary main effects model containing all other covariates 
associated with the outcome had been fitted.  We use the same model building process as 
described in Section 3.2.   
 
Table 4.2.1 shows the results of the univariable analysis.   Based on the overall p-value the 
covariates chosen were age, duration of the first dialysis, race, disease category, state of 
residence at the first RRT, first donor type and era of first treatment.   
 
Table 4.2.2 shows the results of fitting a multivariable model using the covariates chosen in 
the univariable analysis.  Looking at the overall p-values we see that ‘primary disease 
category’ and ‘duration of the first dialyses’ were the two covariates with the largest p-
values.  We next checked for confounding by dropping the two covariates from the model 
and running the regression and seeing if that changes the coefficients of the remaining 
covariates by more than 20%.  Our check revealed that they were not important 
confounders and so they were dropped permanently from our model.   
 
In our reduced model ‘State of residence at the first renal replacement therapy’ was the 
only non-significant covariate.  We checked for confounding by dropping this covariate and 
running the regression and seeing if that changes the coefficients of the other remaining 
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covariates by more than 20%.  Our check revealed that it was not an important confounder 
and so was dropped permanently form our model.  
 
We next added back, one at a time, the covariates that did not meet the criteria of 25% in 
the univariable analysis.  The covariate added back was gender.  Gender was still not 
significant and so we removed it permanently from the model.   
 
We next fitted the model and tested the proportional hazards assumption.  Table 4.2.3 
presents the results of the test.  We saw that the time-constant covariate ‘first donor type’ 
strongly violated (p-value < 0.01) the proportional hazards assumption.  Thus we needed to 
modify the model to account for the interaction between time and ‘first donor type’.  From 
the KM graph for survival stratified on the covariate (please see Appendix 1.6) we saw that 
the graft survival from a living donor has a different rate of decline than the rate from a 
deceased donor.  We initially fitted both a linear and quadratic interaction with time but the 
quadratic interaction was not significant and so we dropped it from the model.  We also 
saw that the hazard of era 1990-99 relative to the era 1980-89 may have changed over the 
observed time.  Since the other eras did not strongly violate the proportion hazards 
assumption we made a decision to leave it the way it was and consequently got an average 
effect of the hazard of 1990-99 relative to 1980-89 over the observed time.   
 
Table 4.2.4 shows the results of retesting for violations of the proportional hazards 
assumption after fitting the new model with the linear interaction of ‘first donor type’ with 
time.  We saw that the p-value of the global test was 0.02 and this was non-significant at 
the 1% level of significance.  Thus there was no strong evidence to suggest that the PH 
assumption was strongly violated.   
 
Table 4.2.5 presents the results of fitting the final multivariable model.  The significant risk 
factors identified for a first kidney transplant failure were age group at the first transplant, 
race, era of first renal replacement therapy, and first donor type i.e. living or deceased.  The 
effect of the first donor type on the first kidney graft survival changes over the life of the 
graft.  A first post-first transplant cancer, however, did not increase the hazard of a first 
kidney graft failure.   
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Table 4.2.1 Univariable Analysis for Time to First Kidney Graft Failure 
Covariate 
Reference 
Level Level 
Hazard
Ratio 
HR 
LCL 
HR 
UCL 
Overall 
P-value 
Post-transplant 
cancer 
No Yes 1.26 0.78 2.03 0.342 
Age group at the 
1st Tx Date 
10 to 14 <5 0.55 0.38 0.79 0.001 
  5 to 9 0.85 0.66 1.09  
  15 to 19 1.09 0.92 1.30  
  >19 0.85 0.68 1.06  
Duration of first 
dialysis 
0 days Q1: Less than six months 1.79 1.33 2.41 <0.001 
  Q2: Six months to one year 1.87 1.38 2.53  
  Q3: One year to two years 1.87 1.38 2.54  
  Q4: Greater than two years 1.55 1.14 2.11  
Gender Female Male 1.00 0.87 1.14 0.964 
Race Caucasians Indigenous and Pacific 
Islanders 
1.87 1.49 2.35 <0.001 
  Asians 0.66 0.42 1.04  
Primary Disease 
category 
Glomerulonephritis Cystic/Hereditary 0.76 0.58 0.99 0.035 
  Reflux 0.97 0.82 1.16  
  Interstitial Nephritis 0.67 0.32 1.42  
  Congenital/Urological 0.72 0.58 0.88  
  Cancer related 0.00 0.00 2.25E
114 
 
  Other/Uncertain 0.92 0.72 1.18  
State of 
residence at the 
first RRT 
Australia New Zealand 1.17 0.98 1.39 0.186 
  Overseas 0.83 0.43 1.61  
First donor Deceased donor Living donor 0.51 0.43 0.59 <0.001 
Era of first 
treatment 
1980 to 1989 1963 to 1979 1.08 0.92 1.27 <0.001 
  1990 to 1999 0.61 0.51 0.73  
  2000 to 2006 0.22 0.14 0.33  
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Table 4.2.2 Initial Multivariable Analysis  
Covariate 
Reference 
Level Level 
Hazard
Ratio 
HR 
LCL 
HR 
UCL 
Overall
P-value
Age group at the 1st 
Tx Date 
10 to 14 <5 0.81 0.56 1.19 0.066 
  5 to 9 0.98 0.76 1.27  
  15 to 19 0.97 0.81 1.16  
  >19 0.72 0.57 0.92  
Duration of first 
dialysis 
0 days Q1: Less than six months 1.11 0.81 1.53 0.572 
  Q2: Six months to one year 1.09 0.78 1.51  
  Q3: One year to two years 1.09 0.78 1.51  
  Q4: Greater than two years 0.93 0.66 1.32  
Race Caucasians Indigenous and Pacific 
Islanders 
1.95 1.52 2.49 <0.001 
  Asians 0.86 0.54 1.38  
Primary Disease 
category 
Glomerulonephritis Cystic/Hereditary 0.83 0.63 1.09 0.708 
  Reflux 0.94 0.79 1.12  
  Interstitial Nephritis 0.92 0.43 1.95  
  Congenital/Urological 0.89 0.71 1.11  
  Cancer related 0.00 0.00 3.72E118  
  Other/Uncertain 1.09 0.85 1.40  
State of residence at 
the first RRT 
Australia New Zealand 1.15 0.95 1.38 0.346 
  Overseas 1.12 0.52 2.40  
First donor Deceased donor Living donor 0.57 0.47 0.68 <0.001 
Era of first treatment 1980 to 1989 1963 to 1979 0.98 0.83 1.17 <0.001 
  1990 to 1999 0.71 0.59 0.86  
  2000 to 2006 0.27 0.17 0.42  
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Table 4.2.3 Test of the Proportional Hazards Assumption 
  rho chi2 df Prob>chi2
Age group at first 
Transplant          
<5 -0.055 2.54 1 0.111 
5 to 9 0.008 0.05 1 0.825 
15 to 19 -0.056 2.54 1 0.111 
>19 -0.080 5.02 1 0.025 
Race                       
Ind. & PI 0.002 0.00 1 0.960 
Asians 0.031 0.81 1 0.367 
Era of first  
Treatment              
1963-79 0.083 5.73 1 0.017 
1990-99 0.098 8.57 1 0.003 
2000-06 0.018 0.28 1 0.597 
First donor type           
Living 0.121 11.42 1 0.001 
Post-tx cancer -0.060 3.00 1 0.083 
Global test   46.40 11 <0.001 
 
 
Table 4.2.4 Test of the Proportional Hazards Assumption for model with the donor 
type and time interaction term 
  rho chi2 df Prob>chi2
Age group at first 
Transplant          
<5 -0.047 1.83 1 0.18 
5 to 9 0.016 0.20 1 0.65 
15 to 19 -0.044 1.58 1 0.21 
>19 -0.077 4.74 1 0.03 
Race      
Ind. & PI  0.003 0.01 1 0.93 
Asians  0.031 0.82 1 0.37 
Era of first  
Treatment               
1963-79 0.075 4.70 1 0.03 
1990-99 0.109 10.42 1 0.00 
2000-06 0.033 0.95 1 0.33 
First donor type           
Living -0.004 0.01 1 0.90 
Donor type & time 
Interaction term  -0.041 1.33 1 0.25 
Post-tx cancer     -0.059 2.92 1 0.09 
Global test    0.69 12 0.02 
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Table 4.2.5 Final Multivariable Analysis for Time to First Kidney Graft Failure 
  
Reference 
Level Level 
Hazard 
Ratio 
HR
LCL 
HR 
UCL Estimate P-value 
Overall
P-value
Post-transplant 
cancer 
No Yes 1.48 0.91 2.40 0.39 0.115 0.115 
Age group at the 
1st Tx Date 
10 to 14 <5 0.83 0.57 1.20 -0.09 0.548 0.012 
  5 to 9 1.01 0.78 1.31 0.11 0.246  
  15 to 19 1.01 0.85 1.20 0.11 0.094  
  >19 0.71 0.57 0.89 -0.24 0.006  
Race Caucasians Indigenous 
and Pacific 
Islanders 
2.05 1.62 2.59 0.55 <0.001 <0.001 
  Asians 0.81 0.51 1.28 -0.38 0.017  
Era of first 
treatment 
1980 to 1989 1963 to 1979 1.04 0.88 1.22 0.40 <0.001 <0.001 
  1990 to 1999 0.71 0.59 0.86 0.03 0.758  
  2000 to 2006 0.31 0.20 0.49 -0.79 <0.001  
First donor Deceased 
donor 
Living donor 0.39 0.31 0.49 -0.48 <0.001 <0.001 
Donor Type 
times Time 
0 0 1.07 1.04 1.10 0.07 <0.001 <0.001 
 
Caucasians had a hazard of a first transplant failure that was half (95% CI, 0.4-0.6) the 
hazard of the Indigenous and Pacific Islanders.  Caucasians and Asians had hazards that 
were not significantly different.  The less-than-five-year-olds, five-to-nine-year-olds, ten-
to-fourteen- year-olds, and the fifteen-to-nineteen-year-olds had hazards that were not 
significantly different from each others but were significantly greater than the hazard of the 
greater-than-nineteen-year-olds.  The renal replacement treatment (RRT) begun in earlier 
eras (1963-79 and 1980-89 were not significantly different from each other but were higher 
than the hazards in the later eras (19990-99 and 2000-06) and the hazards grew 
progressively less over time.  A person whose graft was from a living donor had a hazard 
that was initially just 0.4 times (95% CI, 0.3-0.5) the hazard of a person whose graft was 
from a deceased donor; this hazard, however, increased by 7% each year of graft survival 
relative to the hazard associated with a deceased donor.   
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In Figure 4.2.1 we clearly see that the hazard among ‘indigenous and pacific islanders’ was 
much higher than the hazard among Asians and Caucasians.   
 
Figure 4.2.1 Hazard of a First Kidney Transplant Failure by Race 
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In Figure 4.2.2 we see that in the eras 1963-79 and 1980-89 the hazard of a first transplant 
failure seemed to be equal.  This hazard became lower in the era 1990-99 and even lower in 
the era 2000-06.   
 
Figure 4.2.2 Hazard of a First Kidney Transplant Failure by Treatment Decade 
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In Figure 4.2.3 we see that the five-to-nine-year-olds, ten-to-fourteen- year-olds, and the 
fifteen-to-nineteen-year-olds had the same hazard for a first kidney transplant failure which 
was higher than the hazard of the less-than-five-year-olds and the greater-than-nineteen-
year-olds. 
 
Figure 4.2.3 Hazard of a First Kidney Transplant Failure by Age Group at First 
Transplant 
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5.  Time to Death 
5.1  Mortality Rates 
We begin the process of analyzing mortality by doing an exploratory analysis on mortality 
rates.  Since this was just an exploratory analysis no formal analyses was provided. 
 
In the calculation of mortality rates in Table 5.1, for persons who had a post-onset of ESKD 
cancer we, we only added to the person years at risk of death, his time after the cancer was 
diagnosed; the time before the cancer was not included in the analysis as that time did not 
increase his/her risk of dying because of a post-cancer.  In Appendix 1.8 we provide a table 
where the time before the cancer was diagnosed was added to the sum of the person-years 
at risk of death to the group which did not have a cancer.   
 
From Table 5.1 we can see that the mortality rates among persons with post-onset of ESKD 
cancer was more than double the mortality rates among persons with no post-onset of 
ESKD cancer across almost all patient characteristics.  Among persons with no cancer post-
onset, there was no difference in the mortality rates between males and females; however 
among persons with cancer post-onset there seems to be a difference with males having a 
higher mortality rate than females.  The mortality rate among the less-than-five-year-olds 
who had cancer was very high compared to the other age groups.  Among patients who did 
not have a post-onset cancer, the persons who had a transplant as their first renal 
replacement therapy (RRT) had a higher risk of death than patients who had a dialysis as 
their first RRT, whereas among persons who did have a cancer post-onset, persons with 
peritoneal dialysis as their first RRT had a higher risk of death than persons who had either 
hemodialysis or a transplant as their first RRT.   Among persons who did not have a cancer 
post-onset and received a kidney transplant, those who received their first transplant from a 
living donor had a lower risk of death than those who received theirs from a deceased 
donor.   
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Table 5.1 Mortality Rate 
 No post-ESKD cancer Post-ESKD cancer 
Patient characteristic 
Patient-
years 
at risk 
Number 
of 
deaths 
Mortality
rate 
(per 1000 
patient 
years) 
Patient-
years 
at risk 
Number 
of 
deaths 
Mortality
rate 
(per 1000 
patient 
years) 
Gender Female 9874 233 23.6 345 19 55.1 
 Male 12758 268 21 298 26 87.2 
Age group < 1 246 15 61 11 0 0 
 1 to 4 1270 30 23.6 6 2 333.3 
 5 to 9 3190 63 19.7 11 2 181.8 
 10 to 14 6163 122 19.8 107 10 93.5 
 15 to 19 11762 271 23 507 31 61.1 
Race Caucasians 20007 414 20.7 579 44 76 
 Indigenous and Pacific 
Islanders 
1858 70 37.7 20 1 50 
 Asians 767 17 22.2 44 0 0 
First 
treatment 
group 
Peritoneal Dialysis 10344 227 21.9 177 19 107.3 
 Hemodialysis 10539 258 24.5 434 24 55.3 
 Transplant 1749 16 9.1 32 2 62.5 
Era of first 
treatment 
1963 to 1979 6628 227 34.2 290 25 86.2 
 1980 to 1989 8936 169 18.9 210 13 61.9 
 1990 to 1999 5696 80 14 129 6 46.5 
 2000 to 2006 1371 25 18.2 13 1 76.9 
State of 
residence at 
the first RRT 
Australia 18267 387 21.2 485 37 76.3 
 New Zealand 4105 108 26.3 135 8 59.3 
 Overseas 260 6 23.1 23 0 0 
First donor Deceased donor 14529 305 21 389 30 77.1 
 Living donor 7341 74 10.1 253 14 55.3 
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Table 5.1 Mortality Rate (continued) 
Primary 
Disease 
category 
Glomerulonephritis 8636 207 24 331 23 69.5 
 Cystic/Hereditary 1953 41 21 41 2 48.8 
 Reflux 5396 101 18.7 211 10 47.4 
 Interstitial Nephritis 240 9 37.5 7 1 142.9 
 Congenital/Urological 3959 68 17.2 46 6 130.4 
 Cancer related 69 3 43.5 . 0 . 
 Other/Uncertain 2378 72 30.3 6 3 500 
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5.2 Incidence of Death among ESKD Patients 
In this section we provide the incidence proportion of death as a continuous function of 
time using the Kaplan-Meier Failure Curve for Time to Death.  The analysis variable here 
was ‘time to death from the onset of ESKD’.  Using a KM curve to calculate the incidence 
proportion was quite necessary here as there were, expectedly, a large number of censored 
observations.  The total analysis time at risk for death was 24,631.12 years for the 1,930 
subjects we have in our data and 546 patients died (the time includes the time before cancer 
for patients who did get a post-onset cancer).  Thus the incidence rate was 22.17 per 1000 
patient years.   
Figure 5.2.1 provides us with incidence proportion as a continuous function of time.  The 
incidence proportion was defined here as the proportion who die.  The graph shows that 
over a five year period from the onset of ESKD the incidence proportion was 15%, over a 
ten year period it was 20%, over a 15 year period it was 30%, over a 20 year period it was 
35%, over a 30 year period it was 50%, and over a 35 year period it was 60%.  Thus the 
incidence proportion increases at a constant rate over time.   
 
Figure 5.2.1 Kaplan-Meier Survival Curve  
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From Table 5.2.1 we see that the median survival time was 31 years (95% CI, 28.9-32.7) 
and at 13 years 75% of the patients were still alive.   
 
Table 5.2.1 Quartiles of Survival Time 
      Survival Times   
Time at Risk 
Incidence 
Rate 
No. of 
subjects 25% 50% 75% 
95% CI 
50% Survival 
24631.12 0.0222 1930 13.42 31.04   (28.89, 32.70) 
 
 
In Figure 5.2.2 we see that the hazard of death was relatively constant.   
 
Figure 5.2.2 Smoothed Hazard Estimate Graph 
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The Epanechnikov Kernel function is used to smooth the hazard estimate 
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5.3 Identifying Cancer as a Risk Factor for Survival 
 
A Cox Proportional Hazards model was fitted with the outcome variable being ‘time to 
death’.  The covariates considered for our model were pre-onset of ESKD cancer flag, first 
post-onset of ESKD cancer, gender, race, age group at onset of ESKD, treatment type 
(time-varying and categorical), era of first treatment, and primary disease category.  The 
‘first post-onset of ESKD cancer’ was a binary time-varying covariate which took on the 
value of one from the time during ESKD when the person was diagnosed with his/her first 
post-onset cancer, and zero otherwise.  For the univariable analysis we used the binary form 
of the time-varying covariate ‘treatment type’ which took on the value one after a person 
has his/her first kidney transplant, and zero otherwise.  (See Appendix 1.4 for description of 
the covariates). 
 
Since we were interested in estimating the additional effect of cancer adjusting for other 
covariates, we excluded the cancer variable from the variable selection process and brought 
them in after the preliminary main effects model containing all other variables associated 
with the outcome had been fitted.  We used the same model building process as described 
in Section 3.2.   
 
Table 5.3.1 shows the results of the univariable analysis.  Based on the overall p-value, the 
only covariate not chosen for the multivariable analysis was gender.   
 
Table 5.3.2 shows the results of fitting a multivariable model using the covariates chosen in 
the univariable analysis.  Instead of using the binary time varying form of ‘treatment type’ 
we used the same categorical time varying form used in the ‘time to first post-onset of 
ESKD cancer’ analysis in Section 3.2.  Looking at the overall p-values we see that all the 
covariates were significant at the 5% level and so we did not exclude any covariate from 
our model.   
 
‘Gender’ was added into the model and the new model was estimated but ‘gender’ was still 
not significant and so was excluded.   
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Table 5.3.1 Univariable Analysis for Time to Death (from onset of ESKD) 
Covariate 
Reference 
Level Level 
Hazard
Ratio 
HR 
LCL 
HR 
UCL 
Overall
P-value 
Patients with at 
least one pre-
ESKD cancer 
No Yes 2.15 0.89 5.19 0.089 
Post-onset of 
ESKD cancer 
No Yes 3.81 2.76 5.25 <0.001 
Gender Female Male 0.91 0.77 1.08 0.271 
Race Caucasians Indigenous and Pacific 
Islanders 
1.72 1.34 2.21 <0.001 
  Asians 0.93 0.57 1.51  
Primary Disease 
category 
Glomerulonephritis Cystic/Hereditary 0.88 0.63 1.22 0.005 
  Reflux 0.79 0.63 0.99  
  Interstitial Nephritis 1.66 0.88 3.12  
  Congenital/Urological 0.75 0.58 0.98  
  Cancer related 1.65 0.53 5.15  
  Other/Uncertain 1.26 0.97 1.64  
Age group 5 to 9 years < 1 years 2.42 1.38 4.25 0.022 
  1 to 4 years 1.20 0.78 1.83  
  10 to 14 years 1.00 0.75 1.35  
  15 to 19 years 1.14 0.87 1.49  
Era of first 
treatment 
1980 to 1989 1963 to 1979 1.69 1.38 2.05 <0.001 
  1990 to 1999 0.64 0.49 0.83  
  2000 to 2006 0.57 0.37 0.87  
Treatment Type Dialysis Transplant 0.20 0.17 0.25 <0.001 
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Table 5.3.2 Initial Multivariable Analysis  
Covariate 
Reference 
Level Level 
Hazard
Ratio 
HR
LCL 
HR 
UCL 
Overall 
P-value 
Race Caucasians Indigenous and Pacific 
Islanders 
1.54 1.18 2.01 0.006 
  Asians 1.17 0.71 1.92  
Primary Disease 
category 
Glomerulonephritis Cystic/Hereditary 1.18 0.84 1.65 0.034 
  Reflux 0.83 0.66 1.04  
  Interstitial Nephritis 1.89 1.00 3.58  
  Congenital/Urological 0.92 0.70 1.21  
  Cancer related 2.18 0.67 7.09  
  Other/Uncertain 1.23 0.94 1.62  
Age group at onset 
of ESKD 
5 to 9 years < 1 years 3.49 1.94 6.30 <0.001 
  1 to 4 years 1.60 1.04 2.48  
  10 to 14 years 0.88 0.65 1.19  
  15 to 19 years 0.93 0.70 1.22  
Era of first 
treatment 
1980 to 1989 1963 to 1979 1.87 1.52 2.30 <0.001 
  1990 to 1999 0.66 0.51 0.87  
  2000 to 2006 0.59 0.38 0.92  
Treatment Type D1: Dialysis just 
before first 
transplant 
T1: 1st Tx  0.42 0.31 0.58 <0.001 
  D2: Dx just after 1st Tx  3.08 2.26 4.20  
  T2: 2nd Tx  0.77 0.50 1.18  
  D3+: All Dx after 2nd Tx  3.00 2.07 4.35  
  T3+: 3rd or higher Tx  0.64 0.32 1.30  
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We tested whether the different dialysis periods had equal risks and similarly whether the 
different transplant periods had equal risks.  If the transplant periods have equal risk then 
we shall create one covariate for transplant period.  D2 risk was compared to D3+ risk to 
see if there was a significant difference; if there was then we look at a comparison of the 
two combined versus D1 and if this was also not significant then merge them into one.  If 
both, dialysis periods and transplant periods were not different, then we shall revert back to 
our binary covariate for dialysis versus transplant.   
 
From Table 5.3.3 we see that T2 was not significantly different from T3+ and so can be 
combined.  We also see that D2 was not significantly different from D3+ and so they can 
be combined as well.  We also see that D2+ was significantly different from D1 and T2+ 
was significantly different from T1.  Thus we shall not combine any further. 
 
Table 5.3.3 Test if the risks in the treatment periods were equal 
 
Wald 
ChiSq DF P-Value
T1 = T2 = T3+:   Tx periods have equal risk  10.888 2 0.004 
T2 = T3+:            2nd Tx = 3rd+ Tx  0.264 1 0.608 
D2 = D3+:           Dx just after 1st Tx risk = All Dx after 2nd Tx risk 0.035 1 0.853 
  
 
Hazard
Ratio 
HR
LCL
HR 
UCL P-Value 
T1 vs D1:      1st Tx vs Dialysis just before 1st Tx  0.42 0.31 0.58 <0.001 
D2+ vs D1:   All Dx after 1st Tx vs Dx just before 1st tx  3.06 2.26 4.16 <0.001 
T2+ vs D1:    2nd Tx+ vs Dx just before 1st Tx  0.75 0.50 1.13 0.164 
 
Linear Test 
Wald
ChiSq DF P-Value
T1 vs T2+:   1st Tx = 2nd+ Tx  10.700 1 0.001 
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We next include the cancer covariates in our chosen model, fit the model and test the 
proportional hazards assumption.  Table 5.3.4 presents the results of the test of the PH 
assumption.  We see that none of the covariates violate the proportional hazards 
assumption.   
 
Table 5.3.4 Test of the Proportional Hazards Assumption 
  rho chi2 df Prob>chi2 
Pre-ESKD cancer -0.002 0.00 1 0.963 
Post-onset of ESKD Cancer -0.051 1.54 1 0.215 
Race      
Indigenous & PIs 0.032 0.54 1 0.463 
Asians -0.042 1.07 1 0.300 
Primary Disease      
Cystic/Hereditary -0.002 0.00 1 0.961 
Reflux 0.014 0.11 1 0.736 
Interstitial Nephritis 0.032 0.59 1 0.443 
Cong/Urological 0.069 2.54 1 0.111 
Cancer related -0.008 0.04 1 0.835 
Other/Uncertain -0.076 3.16 1 0.075 
Age-group       
<1 years -0.046 1.17 1 0.280 
1 to 4 years -0.058 1.83 1 0.177 
10 to 14 years -0.029 0.47 1 0.493 
15 to 19 years -0.007 0.02 1 0.877 
       
Era of first treat      
1963 to 1979 -0.117 7.58 1 0.006 
1990 to 1999 -0.046 1.22 1 0.270 
2000 to 2006 -0.017 0.16 1 0.686 
Treatment Periods      
T1: First Tx -0.022 0.32 1 0.571 
D2+: All Dx post 1st Tx -0.048 1.62 1 0.203 
T2+: 2nd or higher Tx -0.013 0.11 1 0.744 
Global test   27.09 20 0.133 
 
Table 5.3.5 presents the results of fitting the final multivariable model.  The significant risk 
factors (at the 5% level) identified for death were pre-onset cancer, post-onset cancer, race, 
age group at onset of ESKD, era of first renal replacement therapy and treatment type.  
Primary disease category was significant at the 10% level.   
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Table 5.3.5 Final Multivariable Analysis for Time to Death (from onset of ESKD) 
Covariate 
Reference 
Level Level 
Hazard
Ratio 
HR
LCL 
HR 
UCL P-value 
Overall
P-value
Patients with at least 
one pre-ESKD cancer 
No Yes 3.83 1.25 11.79 0.019 0.019 
Post-onset of ESKD 
cancer 
No Yes 4.41 3.16 6.15 <0.001 <0.001 
Race Caucasians Indigenous and Pacific 
Islanders 
1.62 1.24 2.11 0.008 0.002 
  Asians 1.02 0.62 1.69 0.399  
Primary Disease 
category 
Glomerulonephritis Cystic/Hereditary 1.20 0.86 1.68 0.780 0.055 
  Reflux 0.84 0.67 1.06 0.040  
  Interstitial Nephritis 1.87 0.99 3.56 0.094  
  Congenital/Urological 0.97 0.74 1.28 0.302  
  Cancer related 1.07 0.26 4.43 0.911  
  Other/Uncertain 1.30 0.98 1.71 0.399  
Age group at onset of 
ESKD 
5 to 9 years < 1 years 3.33 1.84 6.01 <0.001 <0.001 
  1 to 4 years 1.60 1.03 2.47 0.227  
  10 to 14 years 0.85 0.63 1.15 <0.001  
  15 to 19 years 0.88 0.67 1.16 <0.001  
Era of first treatment 1980 to 1989 1963 to 1979 1.90 1.54 2.33 <0.001 <0.001 
  1990 to 1999 0.62 0.47 0.81 <0.001  
  2000 to 2006 0.55 0.35 0.85 0.003  
Treatment Type D1: Dialysis just 
before first 
transplant 
T1: First transplant 0.41 0.30 0.57 <0.001 <0.001 
  D2+: All dialysis after 
first transplant  
3.01 2.22 4.08 <0.001 <0.001 
  T2+: Second or higher 
transplant  
0.76 0.51 1.15 0.194 0.194 
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Patients with at least one pre-onset cancer had a hazard of death that was 3.8 times (95% 
CI: 1.3-11.8) the hazard of patients with no pre-onset cancer.  Patients with at least one 
post-onset-of-ESKD cancer had a hazard of death that was 4.4 times (95% CI: 3.2-6.2) the 
hazard of patients with no post-onset-of-ESKD cancer.   
 
Caucasians had a hazard of death that was 0.6 times (95% CI: 0.5-0.8) the hazard of 
Indigenous and Pacific Islanders.  Caucasians and Asians had hazards that were not 
significantly different from each others.   
 
None of the primary disease categories had hazards that were significantly different from 
each others.   
 
The hazard of death for the ‘<1 years’ age group was 3.3 times that of the ‘5 to 9 years’ age 
group (95% CI: 1.8-6.0).  The hazard for the ‘1 to 4 years’ age group was 60% higher than 
that of the ‘5 to 9 years’ age group (95% CI: 1.0-2.5).  The hazard of death for the ‘5 to 9 
years’ age group was not significantly different from that of the older age groups.  
 
The hazard of death for RRT begun in earlier eras was significantly higher than the hazard 
for RRT begun in later eras.  The hazard of death for persons with the onset of RRT in the 
period ‘1963-79’ was nearly double that of the persons with an onset in the period ‘1980-
89’ (HR 1.9; 95% CI: 1.5-2.3).  The hazard in the period ‘1990-99’ and ‘2000-06’ were 
38% and 45% respectively lower than in the period ‘1980-89’.   
 
The hazard of death for patients with their first donor graft in them was 0.4 times (95% CI: 
0.3-0.6) the hazard for patients who were on dialysis and have not had a transplant.  The 
hazard of death for patients on dialysis at any time after the first graft failure was 3 times 
(95% CI: 2.2-4) the hazard for patients who were on dialysis but had not had a transplant.  
The hazard of death for patients with their second donor graft in them was not significantly 
different from the hazard for patients who were on dialysis and have not had a transplant.   
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1. Project 2 
The risk of cancer and survival relative to that in the general 
population in patients who were under the age of 20 years at the 
onset of ESKD 
1.1 Objectives 
There were several objectives for this project.  These objectives are stated below.   
 
1. To determine the relative survival of patients with ESKD.   
Patients who have ESKD could die of causes that were not related to their disease.  
However the interest was in determining what proportion of the population with ESKD 
who die after a certain period of follow-up, died because he or she acquired ESKD.  
The information we get was probability of dying before t periods of follow-up from 
causes directly associated with the disease/s or the incidence proportion of deaths 
caused by the disease/s in the t periods of follow-up.   
 
2. To determine the Standardized Mortality Ratio (SMR) of patients with ESKD. 
 
Here too we were interested in determining the cause-specific mortality over a certain 
period of time; the difference here is that as opposed to cause-specific incidence 
proportion in relative survival, here we get how many times greater is the mortality 
among patients in our population compared to the mortality in the general population.  
We count the number of deaths in a certain period in our observed sample of patients 
with ESKD and divide that by the amount of deaths we would expect.  We shall 
determine SMR for the all the ESKD patients as well as subgroups of ESKD patients 
based on age at onset of disease, gender, era of onset of the disease, and whether he/she 
had a post-onset-of-ESKD cancer.  The information we get was how much more likely 
a person was to die of ESKD or ESKD and cancer than he/she was to die from any 
other cause.   
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3. To determine the Standardized Incidence Ratio (SIR) of cancer for patients with ESKD. 
 
Here we were interested in determining cause-specific morbidity.  Here we count the 
number of post-onset cancers in a certain period in our observed sample of patients with 
ESKD and divide that by the number of post-onset cancers we would expect.  We shall 
determine SIR for all ESKD patients as well as subgroups of patients based on age at 
onset of disease, gender, era of onset of the disease, and cancer site.  The information 
we get was how much more likely a person with ESKD was to get a post-onset cancer 
compared to the general population. 
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1.2 Data 
All patients in whom renal replacement therapy (RRT) started in Australia or New Zealand 
and who were registered in the ANZDATA registry and who were under the age of 20 
when this therapy began were included in the study.  For relative survival and standardized 
mortality ratios, those patients whose RRT started between January 1 1980 and December 
31 1996 were included in the study; there were 1,495 patients in the dataset out of which 67 
or 4.5 had cancer during ESKD.  For standardized incidence ratios of cancer, those patients 
whose RRT began in Australia between January 1 1982 and December 31 2005 and those 
patients whose RRT began in New Zealand between January 1 1980 and December 31 
2004 were included in the study.   
 
The dataset for the population information used to determine Relative Survival and 
Standardized Mortality Rates consisted of population, deaths, rate of deaths and probability 
of death by age, sex, year (1980 to 2007) and country (New Zealand and Australia).  These 
data came from the Australian Bureau of Statistics (ABS, 2009).  This dataset was merged 
with the ESKD data to calculate the two measures.   
 
The cancer incidence data for Australia came from the Australian Institute of Health and 
Welfare which is Australia’s national agency for health and welfare statistics and 
information (AIHW, 2009).  The dataset consists of the numbers of cancers by year (1982 
to 2005), gender, age group and cancer site.  The cancer incidence data for New Zealand 
came from New Zealand Cancer Registry (NZCR, 2009).  The dataset consists of the 
number of cancers by year (1980 to 2004), gender, age group and cancer site.  These 
datasets was merged with the population dataset for Australia and New Zealand to calculate 
the incidence in the general population in Australia and New Zealand and further merged 
with the ESKD data to calculate Standardized Incidence Ratios for cancers for the 
Australian and New Zealand population.   
 
The inclusion criteria for this project were:  
• Residents of Australia or New Zealand 
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• Renal replacement therapy started in Australia or New Zealand between 1st of January 
1980 and 31st December 2006 for the Relative Survival and Standardized Mortality 
Ratio analyses 
• Renal replacement therapy started in Australia between 1982 and 2005 and in New 
Zealand between 1980 and 2004 for the Standardized Incidence Ratio analysis 
• Under the age of 20 when renal replacement therapy began 
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2. Relative Survival  
In this section we analyze relative survival in patients with ESKD.  For details regarding 
the calculation of relative survival please see Appendix 2.1.   
 
There 1,495 patients whose onset of ESKD was between January 1 1980 and December 31 
2006 and out of these patients 290 died on or before December 31 2006.    
 
As can be seen in Table 2.1 there were 1495 patients at the start of the first year of follow-
up of which 52 patients dropped out either because they were censored or they were lost to 
follow-up.  Thus the effective number at risk during the first year of follow-up was 1469 
(1495 – 52/2).  Of the patients who were at risk, 48 died, and so the interval-specific 
observed survival was 0.967 {(1469 – 48)/1469).  The interval-specific expected survival is 
just the average of the expected survival of all patients in their first year of follow-up given 
their age at that time, the calendar year at that time, their country and gender; i.e. say a male 
patient in Australia who is 25 years old in 1985 in which his first year of follow-up began 
has an expected probability of survival that is the probability of survival of all 25-year old 
males in Australia in 1985.  The interval-specific relative survival is the interval-specific 
observed survival divided by the interval-specific expected survival; for the first year of 
follow-up this would be 0.967/0.999 equal to 0.968.  For the first year of follow-up the 
cumulative observed survival and the cumulative expected survival are just their interval-
specific counterparts.  From the second period of follow-up onwards, the cumulative 
observed survival and the cumulative expected survival are just their interval-specific 
counterparts for the period of follow-up multiplied by their respective values in the 
previous period.  For example for the second period of follow-up the cumulative observed 
survival 0.9447 is just 0.9766 multiplied by 0.967.  The cumulative observed survival at 
any period of follow-up t tells us the probability of surviving t periods of follow-up.  The 
cumulative relative survival at any period t tells us how many times less likely a patient is 
to survive t periods of follow-up compared to a person from the general population who is 
similar in terms of age of the patient at the tth period, gender, calendar year at tth period and 
country.  One minus the cumulative observed survival can be interpreted as the incidence 
proportion of deaths among ESKD patients in t periods of follow-up from any cause, while 
one minus the cumulative relative survival can be interpreted as the incidence proportion of 
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deaths among ESKD patients in t periods of follow-up from causes directly related to 
ESKD.   
 
At the first year of follow-up, patients with ESKD were 3% less likely to survive than 
persons in the general population.  In terms of incidence proportion, all 3% of the ESKD 
patients who died, died from causes directly related to ESKD.  As the years of follow-up 
increases patients with ESKD become less and less likely to survive than persons in the 
general population.   At the 20th year of follow-up, patients with ESKD were 25% less 
likely to survive than persons in the general population.  In terms of incidence proportion, 
in the 20 years of follow-up, of the 27% of deaths among ESKD patients from all causes, 
25% were directly related to ESKD and thus only 2% were from other causes.  Figure 2.1.1 
shows this steady decline in cumulative relative survival and because our sample size was 
large the confidence interval band was tight around it.   
 
Figure 2.1.2 displays the cumulative relative survival of patients with ESKD split by the 
age group they were in at the onset of ESKD.  We see that the cumulative relative survival 
of patients who were infants at the onset of ESKD had a lower initial level than the other 
age groups i.e. the cumulative relative survival at the first year of follow-up was lower than 
that of the other age groups; the rate of decline in the first seven years was steeper than the 
other age groups i.e. their chance of survival relative to the general population grew worse 
over the seven years of years of follow-up at a faster rate than that of the other age groups; 
after seven years the relative survival did not decline further.  The cumulative relative 
survival of patients who were 1 to 4 years old at the onset of ESKD was high (nearly one) 
at the first year of follow-up, but declined quite rapidly in the first four years of follow-up 
to around 0.85; after four years the decline was gradual.  The cumulative relative survival 
of the older age groups had initial levels that were close to one, but declined gradually over 
the follow-up years.   
 
Figure 2.1.3 shows that the cumulative relative survival of females was lower than that of 
males for all the follow-up years.  Thus during the period of observation females had a 
higher probability of dying from causes directly related to ESKD than males.  The mortality 
rate of females was lower than that of males in the general population but in the ESKD 
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population this rate was the same (as seen from the results of Project 1); thus the mortality 
rate for females from causes directly related to ESKD was higher.   
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Table 2.1 Life Table Estimates of Patient Survival for Patients with ESKD  
Interval L D W 
Effective 
number 
at risk 
Interval-specific 
observed 
survival 
Cumulative 
observed 
survival 
Interval-specific 
expected 
survival 
Cumulative 
expected 
survival 
Interval-specific 
relative survival
Cumulative 
relative 
survival 
Lower 
95% CI 
for CR 
Upper 
95% CI 
for CR 
0.0 - 1.0 1495 48 52 1469 0.96732 0.96732 0.99925 0.99925 0.96805 0.96805 0.95759 0.97601 
1.0 - 2.0 1395 32 52 1369 0.97663 0.94471 0.99938 0.99863 0.97723 0.94601 0.93291 0.95666 
2.0 - 3.0 1311 20 54 1284 0.98442 0.93000 0.99938 0.99801 0.98504 0.93185 0.91730 0.94398 
3.0 - 4.0 1237 17 68 1203 0.98587 0.91686 0.99937 0.99738 0.98649 0.91926 0.90351 0.93261 
4.0 - 5.0 1152 20 60 1122 0.98217 0.90051 0.99937 0.99675 0.98280 0.90345 0.88627 0.91823 
5.0 - 6.0 1072 18 52 1046 0.98279 0.88502 0.99936 0.99611 0.98342 0.88847 0.87002 0.90453 
6.0 - 7.0 1002 14 48 978 0.98569 0.87235 0.99933 0.99544 0.98635 0.87634 0.85689 0.89341 
7.0 - 8.0 940 10 48 916 0.98908 0.86282 0.99930 0.99475 0.98977 0.86738 0.84717 0.88519 
8.0 - 9.0 882 10 51 857 0.98832 0.85275 0.99928 0.99404 0.98903 0.85787 0.83685 0.87648 
9.0 - 10.0 821 10 48 797 0.98745 0.84205 0.99928 0.99332 0.98816 0.84771 0.82583 0.86717 
10.0 - 11.0 763 11 47 740 0.98513 0.82953 0.99927 0.99260 0.98585 0.83571 0.81281 0.85618 
11.0 - 12.0 705 12 48 681 0.98238 0.81491 0.99925 0.99185 0.98312 0.82161 0.79751 0.84324 
12.0 - 13.0 645 10 47 622 0.98391 0.80180 0.99922 0.99107 0.98468 0.80902 0.78384 0.83171 
13.0 - 14.0 588 6 41 568 0.98943 0.79332 0.99919 0.99027 0.99022 0.80111 0.77519 0.82452 
14.0 - 15.0 541 6 57 513 0.98829 0.78403 0.99917 0.98945 0.98911 0.79239 0.76561 0.81663 
15.0 - 16.0 478 8 40 458 0.98253 0.77034 0.99915 0.98861 0.98337 0.77921 0.75108 0.80474 
16.0 - 17.0 430 3 45 408 0.99264 0.76467 0.99911 0.98773 0.99352 0.77417 0.74542 0.80028 
17.0 - 18.0 382 3 23 371 0.99190 0.75847 0.99909 0.98683 0.99280 0.76860 0.73912 0.79539 
18.0 - 19.0 356 5 40 336 0.98512 0.74719 0.99908 0.98592 0.98603 0.75786 0.72699 0.78594 
19.0 - 20.0 311 5 47 288 0.98261 0.73419 0.99908 0.98501 0.98352 0.74537 0.71274 0.77508 
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Figure 2.1.1 Cumulative Relative Survival of Patients with ESKD  
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Figure 2.1.2 Cumulative Relative Survival of Patients with ESKD by Age Group 
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Figure 2.1.2 Cumulative Relative Survival of Patients with ESKD by Age Group 
(continued) 
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Figure 2.1.3 Cumulative Relative Survival of Patients with ESKD by Gender 
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3. Standardized Mortality Ratios 
There were 1,495 patients whose onset of ESKD was between January 1 1980 and 
December 31 2006 and out of these patients 290 died on or before December 31 2006.   In 
that same period 67 patients with ESKD also had cancer and out of these 20 patients died 
on or before December 31 2006.   
 
The SMR for all patients with ESKD was calculated in the following way.  The column 
‘observed deaths’ was derived from the ESKD dataset for the period January 1 1980 to 
December 31 2006.   The ‘expected deaths’ and the ‘standardized mortality ratio’ were 
calculated in the following way.  Each person’s follow-up period in the ESKD dataset from 
the onset of ESKD to the time either he/she dies or was censored was split by age group 
and calendar year and then sorted by country (New Zealand ad Australia), gender, age 
group and calendar year.  A separate population dataset provides the death rates (per 
100,000 person-years) among patients in strata by country, gender, age group and calendar 
year; for example the dataset has for males in Australia who were infants in the year 1980, 
a rate of x deaths per 100,000 person-years.   This population dataset was sorted by 
country, gender, age group and calendar year and merged with our split ESKD dataset.  We 
then count the number of patients in each stratum and then multiply that number by the rate 
of deaths per person-year to come up with the expected number of deaths in each stratum. 
The expected deaths in each of these strata were then added together to come up with the 
‘expected deaths’.  Standardized Mortality Ratio (SMR) was derived by dividing the 
‘observed deaths’ with the ‘expected deaths’.   
 
The SMR for a subgroup, say ‘1 to 4 years’, was derived by taking a subset from the ESKD 
database whose onset of ESKD began when they were between one and four years old.  
The steps to calculate the SMR for that subgroup then follows the same process as was 
used to calculate the SMR for all patients with ESKD.   
   
The results of Table 3.1 are shown graphically in Figure 3.1.  From this table and figure we 
see that the SMR of patients with ESKD and a post-onset cancer (SMR, 76.1; CI, 49.1-118) 
was much higher than the SMR of patients with effectively just ESKD (SMR, 23.7; CI, 
21.1-26.6).  Thus the risk of dying for patients with a post-onset cancer and ESKD from 
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causes directly related to cancer and/or ESKD was much higher than the risk of dying for 
patients with ESKD from causes directly related to ESKD.   
 
Table 3.1 Standardized Mortality Ratios 
Population Level 
Observed 
Deaths 
Expected 
Deaths 
Standard Mortality 
Ratio  
(with CIs) 
All patients with ESKD  290 12.25 23.68 (21.11, 26.57) 
       
All patients with ESKD Age at onset of ESKD     
  Infant 15 0.31 48.89 (29.47, 81.10) 
  1 to 4 years 27 0.66 40.62 (27.86, 59.24) 
  5 to 9 years 34 1.14 29.86 (21.33, 41.79) 
  10 to 14 years 65 3.09 21.06 (16.51, 26.85) 
  15 to 19 years 149 7.05 21.13 (18.00, 24.82) 
       
All patients with ESKD Gender     
  Male 149 9.27 16.08 (13.69, 18.88) 
  Female 141 2.98 47.35 (40.14, 55.85) 
       
All patients with ESKD Era at onset of ESKD     
  1980-89 180 7.95 22.66 (19.58, 26.22) 
  1990-99 84 3.66 22.92 (18.51, 28.39) 
  2000-06 26 0.64 40.79 (27.78, 59.91) 
 
The SMRs of infants and 1 to 4 year olds were much higher than that of the older age 
groups.  The risk of dying from causes directly related to ESKD was much higher among 
children whose onset of ESKD began at an age below five years than among children 
whose onset of ESKD began when they were five years and older.      
 
The SMR of females (SMR, 47.4; CI, 40.1-55.9) was significantly higher than that of males 
(SMR, 16.1; CI, 13.7-18.9).  Female mortality in the general population was significantly 
lower than male mortality.  However among the ESKD patients the mortality rates of males 
and females was the same (as seen in Project 1).  Thus the SMR of females was higher than 
the SMR of females.    
 
The SMR for the 1980s (SMR, 22.7; CI, 19.6-26.2) and 1990s (SMR, 22.9; CI, 18.5-28.4) 
were not significantly different (the CIs overlap).  The SMR of the era 2000-06 appears 
higher but could be in part just a data artifact; persons were censored in December 31 2006 
and so the age distribution of children in this era may be biased towards their being more 
younger children (relative to the other eras), whom, as we have already seen, have higher 
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SMRs.  Another possible reason was that the diagnosis of ESKD was much better in the era 
2000-06.  Thus the worst cases were being diagnosed with ESKD before they died and so 
worst cases were in the ESKD database.  The mortality of the worst cases was now being 
captured by the ESKD database and this in part has made the SMR in this era appear as 
though it had increased.    
 
Figure 3.1 Standardized Mortality Ratios 
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 4. Standardized Incidence Ratios 
There were 1,060 patients whose onset of ESKD began in Australia between January 1 
1982 and December 31 2005, and out of these patients 54 got a post-onset-of-ESKD cancer 
on or before December 31 2005.   There were 275 patients whose onset of ESKD began in 
New Zealand between January 1 1980 and December 31 2004, and out of these patients six 
got a post-onset-of-ESKD cancer.   
 
The SIR of cancer for all patients with ESKD was derived in the following way.  The 
‘observed number of cancers’ was just the sum of the cancers in the ESKD database for 
Australia and New Zealand in their respective periods of observation.  The ‘expected 
number of cancers’ column was derived in the following way.  Each person’s follow-up 
period in the ESKD dataset from the onset of ESKD to the time he/she gets cancer or was 
censored was split by age group and calendar year and then sorted by country (New 
Zealand ad Australia), gender, age group and calendar year.  A separate population dataset 
provides the rates of cancer (per 100,000 person-years) among patients in strata by country, 
gender, age group and calendar year; for example the dataset has for males in Australia who 
were infants in the year 1982, a rate of x cancers per 100,000 persons-years.   This 
population dataset was sorted by country, gender, age group and calendar year and merged 
with our split ESKD dataset.  We then count the number of patients in each stratum and 
then multiply that by the rate of cancers per person-year to come up with the expected 
number of cancers for each stratum.  The expected number in each stratum was then added 
up to give us the ‘expected number of cancers’.  The Standardized Incidence Ratio (SIR) 
was derived by dividing the ‘observed number of cancer’ with the ‘expected number of 
cancers’.   
 
The SIR for a subgroup, say ‘0 to 4 years’, was derived by taking a subset from the ESKD 
database whose onset of ESKD began when they were between zero and four years old.  
The steps to calculate the SIR for that subgroup then follows the same process as was used 
to calculate the SIR for all patients with ESKD.   
 
The results from Table 4.1 are displayed graphically in Figure 4.1.1.  The incidence of 
cancer among patients with ESKD was around 9 times (SIR, 9.21; CI, 7.15-11.86) greater 
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than the incidence in the general population.  The SIR for persons who were under the age 
of five when they began ESKD (SIR, 26.24; CI, 12.51-55.03) was significantly higher than 
the SIR of patients who were in the ‘10 to 14 years’ age group (SIR, 6.86; CI, 3.8-13.4) and 
the ‘15 to 19 years’ age   group (SIR, 8; CI, 6.5-12.4) at the onset of ESKD.  The SIRs of 
the ‘5 to 9 years’, 10 to 14 years’ and 15 to 19 years’ age groups were not significantly 
different from each other.   The SIRs of males and females were the same.  The SIR of 
persons whose onset of ESKD began in the 1980s (SIR, 6.2; CI, 4.3, 9) was significantly 
lower than the SIR of persons whose ESKD began in the 1990s and 2000s.  One possible 
reason for this seemingly counter-intuitive situation was that with the advances in treatment 
persons whose ESKD began in the later eras, were living longer with the disease, and so 
had more chance of acquiring cancer and cancers among ESKD patients occur at a higher 
rate relative to the general population.   
 
Table 4.1 Standardized Incidence Ratios for Cancer 
  
Observed
No. of  
Cancers 
Expected
No. of 
Cancers 
Standardized Incidence 
Ratios  
(with CIs) 
All 60 6.51 9.21 (7.15, 11.86) 
      
Age at onset of ESKD     
0 to 4 years 7 0.27 26.24 (12.51, 55.03) 
5 to 9 years 5 0.53 9.39 (3.91, 22.55) 
10 to 14 years 11 1.60 6.86 (3.80, 12.39) 
15 to 19 years 37 4.11 8.00 (6.52, 12.42) 
     
Gender     
Male 31 3.43 9.03 (6.35, 12.84) 
Female 29 3.08 9.41 (6.54, 13.55) 
      
Era at onset of ESKD     
1980-89 28 4.52 6.20 (4.28, 8.96) 
1990-99 27 1.80 14.99 (10.28, 21.85) 
2000-05 5 0.19 25.79 (10.73, 61.96) 
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Figure 4.1 Standardized Incidence Ratios for Cancer 
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Figure 4.2 displays graphically the results from Table 4.2 which presents SIR by cancer 
site.  Here each person’s follow-up period in the ESKD dataset from the onset of ESKD to 
the time when either he/she gets a cancer in that specific site or was censored, was split by 
age group and calendar year and then sorted by country (New Zealand ad Australia), 
gender, age group and calendar year.  The population dataset provides the rates of cancer in 
specific sites (per 100,000 person-years) among patients in strata by country, gender, age 
group and calendar year; for example the dataset has for males in Australia who were 
infants in the year 1982, a rate of x cancers in the ‘lip and oral cavity’ per 100,000 persons-
years.  The SIRs were derived in an identical manner as was described before.   
 
Table 4.2 shows that the hematological cancers were the dominating cancers accounting for 
half of all cancers.  The incidence of hematological cancers (SIR 24.6; CI, 17.2-35.2) 
among persons with ESKD was almost 25 times higher than the incidence in the general 
population.  The cancers associated with the reproductive and genitourinary systems were 
the second most common cancers accounting for 19 of the 60 cancers.  The incidence of 
this type of cancer (SIR, 11.2; CI, 7.2-17.6) was around 11 times higher than the incidence 
in the general population.  In our sample there were no cancers associated with the ‘lip and 
oral cavity’, ‘respiratory and intra-thoracic’, and ‘neurological’ systems.   
 
Table 4.2 Standardized Incidence Ratios of Cancer by Cancer Site 
  
ICD 
Codes 
Observed
No. of  
Cancer 
Expected 
No. of 
Cancers 
Standardized 
Incidence Ratios  
(with CIs) 
All C00 - C95 60 6.51 9.21 (7.15, 11.86) 
Lip and oral cavity C00 - C14 0 0.23  
Digestive C15 - C25 3 0.35 8.64 (2.79, 26.79) 
Respiratory and Intra-thoracic C30 - C38 0 0.11  
Skin/bone/connective tissue C40 - C48 6 2.10 2.86 (1.28, 6.36 
Reproductive and genitourinary C50 - C67 19 1.70 11.21 (7.15, 17.57) 
Neurological C69 - C72 0 0.40  
Endocrine C73 - C75 2 0.42 4.78 (1.20, 19.11) 
Hematological C81 - C95 30 1.22 24.59 (17.19, 35.16) 
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Figure 4.2 Standardized Incidence Ratios of Cancer by Cancer Sites 
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Discussion 
 
The main aims of Project 1 were to determine if having cancer (before or after the onset of 
ESKD) reduces survival, to specify the main types of cancers that were associated with the 
patients in our study, to determine the incidence proportion of cancer among ESKD 
patients, to determine the risk factors for getting a cancer after the onset of ESKD, and to 
determine if cancer reduces graft survival.   In our analysis we saw that cancer substantially 
increases the risk of dying with patients with cancer either before or after the onset of 
ESKD being four times more likely (HR 3.83; CI, 1.25-11.79) to die at any given point 
than patients with no cancer.  Among the cancers which began before the onset of ESKD, 
the cancers associated with the kidneys accounted for 9 out of 16 or 56% of the cancers.  
Among the cancers which began after the onset of ESKD, the cancers associated with the 
hematological system accounted for 38 out of the 110 or 35% of the cancers and the 
cancers associated with the reproductive and genitourinary systems accounted for a further 
36 out of 110 or 33% of the cancers.  In the first five years of follow-up since the onset of 
ESKD 1.25% of the patients got cancer, in the first 10 years 3.5% of the patients got 
cancer, in the first 15 years 6.25% of the patients got cancer and in the first 20 years 8% of 
the patients got cancer.  The main risk factor for getting a cancer was age at the onset of 
ESKD with the patients who were infants at a substantially greater risk of acquiring cancer 
than the other age groups and patients who were between 5 and 9 years old at a 
substantially lower risk than the other age groups.  Another risk factor for acquiring cancer 
was the type of renal replacement therapy used with patients with a donor kidney graft 
twice as likely to get cancer as patients on dialysis (HR, 1.94; CI, 1.18-3.20).  Lastly we see 
that having a cancer either before the first kidney transplant or during the life of the first 
kidney graft was not associated with graft survival; we can generalize this result to state 
that cancer was not associated with graft survival.     
 
The main aims of Project 2 were to determine the relative survival of patients with ESKD 
and post-onset cancer and to compare it with the relative survival of patients with ESKD, to 
determine the standardized mortality ratio (SMR) of patients with ESKD and post-onset 
cancer and compare it with the SMR of patient with ESKD, to determine the standardized 
incidence ratio (SIR) of post-onset cancer across subgroups of the ESKD population, and to 
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determine the SIR for types of cancers.  Among patients with ESKD (1,495 patients), in the 
20 years of follow-up 25% of the patients died of causes directly related to ESKD; whereas 
among patients with ESKD and cancer (67 patients), in the 20 years of follow-up the 
incidence proportion of deaths was much worse with 62% of the patients dying from causes 
directly related to ESKD and/or cancer.  For both groups, very few patients died from other 
causes and so nearly all the deaths were caused by ESKD and/or cancer.  The mortality rate 
among the ESKD-cancer patients was 76 times the mortality rate of the general population 
(SMR, 76.14; CI, 49.12-118.02) whereas the mortality rate among the ESKD patients was 
24 times the mortality rate of the general population (SMR, 23.68; CI, 21.11-26.57).  Thus 
the mortality rate among the ESKD-cancer patients was three times the mortality rate 
among patients with ESKD.  The cancer rate among ESKD patients was nine times the 
cancer rate in the general population (SIR, 9.21; CI, 7.15-11.86).  ESKD patients under the 
age of five at the onset of ESKD were at very high risk of acquiring cancer (SIR, 26.24; CI, 
12.51-55.03).  Lastly the patients in our population were at a considerable risk of acquiring 
cancer associated with the hematological system (SIR, 24.59; CI, 17.19-35.16). 
 
The study had some limitations.  The population of ESKD patients in our database in the 
later eras were a truer reflection of the population of ESKD patients that the population of 
ESKD patients in the earlier eras as with the improvement in the diagnosis and treatment of 
ESKD [Herwig-Ulf Meier-Kreiesche et al, 2001] a lot more of the patients with rapidly 
progressive kidney disease were being captured in our database than would not have been 
in the earlier eras (they would have died before being entered into the database); thus 
cancer incidence and survival would be overestimated.  An implicit assumption made in 
calculating the relative survival in ESKD-cancer patients is that on average the negative 
effect of cancer on survival does not get worse with time but remains constant.  This may 
not be an unreasonable assumption as some peoples’ cancer does get worse while others go 
into remission and so on average the negative effect of cancer on survival may remain 
constant.   
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Acronyms 
 
ANZDATA Australia and New Zealand Dialysis and Transplant Registry 
CI Confidence Interval 
CRS Cumulative Relative Survival 
CKD Chronic Kidney Disease 
ESKD End Stage Kidney Disease 
GFR Glomeruler Filtration Rate 
ICD9 International Classification of Disease 9th Version 
ICD10 International Classification of Disease 10th Version 
KM Kaplan-Meier 
PH Proportional Hazard 
RRT Renal Replacement Therapy 
SIR Standardized Incidence Ratio 
SMR Standardized Mortality Ratio 
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Appendices  
 
 
Appendix 1.1  Definitions of Survival, KM estimator, and Hazard 
Survival function at any point t reports the probability of surviving beyond time t.   
 
The Kaplan-Meier estimator of Survival is the nonparametric maximum likelihood estimate 
of S(t). It is a product of the form 
 
In the absence of censoring, ni is the number of survivors just prior to time ti whereas with 
censoring, ni is the number of survivors minus the number of losses (censored cases). The 
‘at risk’ population is only those surviving cases that were still being observed (have not 
yet been censored) 
 
Hazard rate is the instantaneous rate of failure.  It is the limiting probability that the failure 
event occurs in a given interval, conditional upon the subject having survived to the 
beginning of that interval, divided by the width of the interval. 
 
Cumulative Hazard at a point t is the sum total of the hazards up to point t.   
 
The Nelson-Aalen estimator of Cumulative Hazard at time t is defined as the sum over all 
distinct failure times less than or equal to t of the ratio of the failures over number at risk at 
each distinct failure time.  
 
The Cox proportional hazard model can be written as: 
h(t) = h0(t)*exp(b1*x1 + ... + bn*xn) where h(t) denotes the resultant hazard, given the 
values of the n covariates for the respective case (x1, x2, ..., xn) and the respective survival 
time (t). The term h0(t) is called the baseline hazard; it is the hazard for the respective 
individual when all independent variable values are equal to zero. This model is made 
linear by dividing both sides of the equation by h0(t) and then taking the natural logarithm 
of both sides: log[h(t)/h0(t)] = b1*x1 + ... + bn*xn 
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Appendix 1.2  Covariates – Time to First post-onset of ESKD Cancer 
Covariates Description 
Pre-ESKD Cancer 
flag 
This binary covariate takes on the value 1 if the subject had a cancer pre-
ESKD  
Gender Gender 
Race Race 
Age Group at the 
onset of ESKD 
Age group at the onset of ESKD 
Treatment Type 1 This binary time-varying covariate takes on the value when the subject has a 
kidney transplant  
Treatment Type 2 This group of binary time-varying covariates was made up of 5 covariates 
C2: 1 when the subject was on his/her 1st Tx, and 0 otherwise 
C3: 1 when the subject was on Dx just after 1st Tx, and 0 otherwise 
C4: 1 when the subject was on his/her 2nd Tx, and 0 otherwise 
C5: 1 when the subject was on all Dx after 2nd Tx, and 0 otherwise 
C6: 1 when the subject was on his/her 3rd + Tx, and 0 otherwise 
Treatment Type 3 This group of binary time-varying covariates was made up of 3 covariates 
C2: 1 when the subject was on his/her 1st Tx, and 0 otherwise 
C3: 1 when the subject was on all Dx just after 1st Tx, and 0 otherwise 
C4: 1 when the subject was on his/her 2nd + Tx, and 0 otherwise 
State of Residence 
at the first RRT 
State of residence at the first RRT 
Decade of First 
Treatment 
Era of first treatment 
Primary Disease 
Category 
Primary disease category 
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Appendix 1.3  Covariates – Time to First Transplant Failure 
Covariates Description 
 
First post-
transplant 
cancer 
This binary time-varying covariate takes on the value 1 when the subject has 
his/her first post-transplant cancer  
Age Group at 
First 
Transplant 
Age group at first transplant 
Duration of 
First Dialysis 
Total duration of the first dialysis was broken up into four quartiles with each level 
of this categorical covariates corresponding to a quartile. 
Gender Gender 
Race Race 
Primary 
Disease 
Category 
Primary disease category 
State of 
Residence at 
the first RRT 
State of residence at the first RRT 
First Donor 
Type 
Status of the donor for the first transplant i.e. deceased or living 
Era of First 
Treatment 
Decade of first treatment 
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Appendix 1.4  Covariates – Time to Death 
Covariates Description 
 
Pre-ESKD Cancer 
flag 
This binary covariate takes on the value 1 if the subject had a cancer pre-
ESKD  
First post-ESKD 
cancer 
This binary time-varying covariate takes on the value 1 when the subject has 
his/her first post-ESKD cancer 
Gender Gender 
Race Race 
Age Group at the 
onset of ESKD 
Age group at the onset of ESKD 
Treatment Type 1 This binary time-varying covariate takes on the value when the subject has a 
kidney transplant  
Treatment Type 2 This group of binary time-varying covariates was made up of 5 covariates 
C2: 1 when the subject was on his/her 1st Tx, and 0 otherwise 
C3: 1 when the subject was on Dx just after 1st Tx, and 0 otherwise 
C4: 1 when the subject was on his/her 2nd Tx, and 0 otherwise 
C5: 1 when the subject was on all Dx after 2nd Tx, and 0 otherwise 
C6: 1 when the subject was on his/her 3rd + Tx, and 0 otherwise 
Treatment Type 3 This group of binary time-varying covariates was made up of 3 covariates 
C2: 1 when the subject was on his/her 1st Tx, and 0 otherwise 
C3: 1 when the subject was on all Dx just after 1st Tx, and 0 otherwise 
C4: 1 when the subject was on his/her 2nd + Tx, and 0 otherwise 
Era of First 
Treatment 
Decade of first treatment 
Primary Disease 
Category 
Primary disease category 
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Appendix 1.5  KM Graphs – Time to First post-onset of ESKD Cancer 
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Appendix 1.5  KM Graphs – Time to First post-onset of ESKD Cancer 
(continued) 
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Appendix 1.6  KM Graphs – Time to First Transplant Failure 
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Appendix 1.6  KM Graphs – Time to First Transplant Failure 
(continued) 
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Appendix 1.7  KM Graphs – Time to Death 
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Appendix 1.7  KM Graphs – Time to Death (Continued) 
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Appendix 1.8 Mortality Rates 
 No post-ESRD cancer Post-ESRD cancer 
Patient characteristic 
Patient-
years 
at risk 
Number 
of 
deaths 
Mortality 
rate 
(per 1000 
patient 
years) 
Patient-
years 
at risk 
Number 
of 
deaths 
Mortality
rate 
(per 1000 
patient 
years) 
Gender Female 10440 233 22.3 345 19 55.1 
 Male 13548 268 19.8 298 26 87.2 
Age group < 1 268 15 56 11 0 0 
 1 to 4 years 1293 30 23.2 6 2 333.3 
 5 to 9 years 3241 63 19.4 11 2 181.8 
 10 to 14 years 6514 122 18.7 107 10 93.5 
 15 to 19 years 12672 271 21.4 507 31 61.1 
Race Caucasians 21328 414 19.4 579 44 76 
 Indigenous and Pacific 
Islanders 
1869 70 37.5 20 1 50 
 Asians 791 17 21.5 44 0 0 
First treatment 
group 
Peritoneal Dialysis 10781 227 21.1 177 19 107.3 
 Hemodialysis 11410 258 22.6 434 24 55.3 
 Transplant 1797 16 8.9 32 2 62.5 
Era of first 
treatment 
1963 to 1979 7420 227 30.6 290 25 86.2 
 1980 to 1989 9338 169 18.1 210 13 61.9 
 1990 to 1999 5853 80 13.7 129 6 46.5 
 2000 to 2006 1377 25 18.2 13 1 76.9 
State of residence 
at the first RRT 
Australia 19366 387 20 485 37 76.3 
 New Zealand 4355 108 24.8 135 8 59.3 
 Overseas 267 6 22.5 23 0 0 
First donor Deceased donor 15455 305 19.7 389 30 77.1 
 Living donor 7749 74 9.5 253 14 55.3 
Primary Disease 
category 
Glomerulonephritis 9330 207 22.2 331 23 69.5 
 Cystic/Hereditary 2047 41 20 41 2 48.8 
 Reflux 5795 101 17.4 211 10 47.4 
 Interstitial Nephritis 242 9 37.2 7 1 142.9 
 Congenital/Urological 4100 68 16.6 46 6 130.4 
 Cancer related . 3 . . 0 . 
 Other/Uncertain 2405 72 29.9 6 3 500 
 
Appendix 2.1  Calculation of Relative Survival 
 
Relative Survival was defined as the observed (all-cause) survival in the patient group 
divided by the expected survival of a comparable group from the general population.  It was 
usual to estimate the expected survival proportion from nationwide population life tables, 
stratified by age, sex and calendar year.  Relative survival represents an estimate of the 
effect of the disease alone on survival.  For example, if the observed survival for a group of 
cancer patients was 50% at 5 years and the expected survival was 80% for the general 
population, then the relative survival would be 50/80, or 63%. So, among the 50% of 
cancer patients who die within 5 years, it was expected that 37% (1−0.63) will die from 
their cancer and 13% from other causes. 
 
Cumulative Relative Survival of each follow-up year (life-table interval) was just the 
Cumulative Observed Survival in each follow-up year divided by the Cumulative Expected 
Survival in the same follow-up year.  We follow each person in our dataset for a maximum 
of 10 years.   
 
Calculation of Cumulative Observed Survival 
The following were taken to arrive at the cumulative observed survival in each interval: 
• We split each person’s observation time into multiple intervals, one for each follow-up 
year ensuring that each observation had the correct value for attained age and attained 
calendar year.  For example, if the onset of ESKD in a 15 year old girl happened in 
1980 and she died in the fifth year of follow-up, then she would be contributing five 
observations where in the fifth observation her attained age at the start of the interval 
would be 19 years and attained year at the start of the interval would be 1984.  
• We note if the person died or withdrew in the last interval.  In our example the person 
died in the fifth interval. 
• We aggregate the number who were living in the start of each of the 10 intervals (nx), 
the number who died in the interval (dx) and the number who withdrew in the interval 
(wx) 
• We then calculate the adjusted number at risk in any interval as the number living at the 
start of the interval minus half the number who withdrew in the interval  
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i.e. nx’ = nx - .5*wx 
• We then calculate the interval specific observed survival as px = (nx’ – dx)/nx’ 
• The cumulative observed survival (lx) for the first interval would just be the interval 
specific observed survival for the first interval (px).  For subsequent intervals, lx for the 
interval is the px for the interval times the lx of the previous interval.   
 
Calculation of Cumulative Expected Survival 
The following were taken to arrive at the cumulative expected survival in each interval: 
• We split each person’s observation time into multiple intervals, one for each follow-up 
year ensuring that each observation had the correct value for attained age and attained 
calendar year.  We also note the person’s gender and country (New Zealand or 
Australia) in which he of she first received renal replacement therapy. 
• We have an external file which has expected probabilities for the population for each 
stratum of country (Australia or New Zealand), gender, age and year (from 1980 to 
2007).   
• We merge our split file with this external file on country, gender, attained age and 
attained year to get the expected probability for each interval of persons’ observation 
time 
• For each of the ten intervals we take the average of the expected probabilities to give us 
the interval-specific expected survival (this is using the Ederer II method to estimate 
expected survival) 
• The cumulative expected survival for the first interval would just be the interval 
specific expected survival for the first interval.  For subsequent intervals, the 
cumulative expected survival  for the interval is the interval-specific expected survival 
for the interval times the cumulative expected survival of the previous interval 
 
Below is an example of the table from a paper by Paul Dickman (Dickman, 2004) on using 
SAS to calculated Relative Survival. 
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We calculate four tables of Relative Survival: 
• Relative Survival for the entire population in our study 
• Relative Survival for the entire population in our study broken down by age at the onset 
of ESKD (0-4 and 5-19) and era of onset (1980-89 and 1990-2006) 
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Appendix 2.2  Formula for Standardized Incidence/Mortality Ratios  
 
Below are definitions taken from the website StatsDirect(2009) http://www.statsdirect.com, 
accessed July 4 2009.   
Indirect standardization was used to calculate the expected mortality rate for the index 
population, given age specific mortality rates from a reference population. 
The confidence intervals are calculated by the exact Poisson method.   Below are the 
equations for Standard Mortality Rates (SMR), the number of expected deaths (e), the 
lower confidence limit of SMR (LL), and the upper confidence limit of SMR. 
 
where χ² ν,α is the (100*α)th chi-square centile with ν degrees of freedom, d is the number 
of observed deaths, ni is the person-time for the ith study group stratum and Ri is the 
reference population rate for the ith stratum. 
 
For SMR the event is death and for SIR of cancer the event is cancer.   
 
